

Supplemental Materials:

Supplemental Figures 1-7

Figure S1: ADA deficient ANA-expressing B cells display the highest frequency of positively charged residues

Figure S2: ADA-deficient mature naive B cells express polyreactive antibodies before and after GT

Figure S3: Defective phosphorylation of Syk and BTK upon TLR stimulation in naïve B cells after inhibition

Figure S4: Defective phosphorylation of ERK1/2 upon BCR stimulation in B cells after ADA inhibition

Figure S5: Defective TLR-induced upregulation of B cell activation markers after ADA inhibition

Figure S6: Defective TLR-induced upregulation of B-cell activation markers after stimulation in presence of cAdo

Figure S7: The majority of ANA expressing B cell clones found in ADA-SCID patients postGT are NeoR-

Supplemental Tables 1- 17

Table S1: Repertoire and reactivity of antibodies from new emigrant B cells of HD27

Table S2: Repertoire and reactivity of antibodies from new emigrant B cells of HD28

Table S3: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 1 before GT

Table S4: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 2 before GT

Table S5: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 3 before GT

Table S6: Repertoire and reactivity of ANA-expressing B cell clones from ADA-SCID patients 1-3 before & after GT

Table S7: Repertoire and reactivity of antibodies from mature naive B cells of HD27

Table S8: Repertoire and reactivity of antibodies from mature naive B cells of HD28

Table S9: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 2 before GT

Table S10: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 3 before GT

Table S11: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 1 after GT

Table S12: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 2 after GT


Table S13: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 3 after GT

Table S14: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 1 after GT

Table S15: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 2 after GT


Table S16: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 3 after GT

Table S17: Serum autoantibodies in ADA-SCID patients 6yrs postGT




Supplemental Figure 1

ADA deficient ANA-expressing B cells display the highest frequency of positively charged residues in their heavy-chain CDR3s. **(A)** New emigrant B cells from ADA deficient patients were grouped into non-autoreactive, autoreactive non-ANA (Hep-2-reactive and/or polyreactive) and ANA clones. The numbers of positively charged residues in immunoglobulin heavy-chain CDR3s were calculated excluding the arginine or lysine found at position 94 in most germline VHs. Pie charts show the proportion of heavy-chain CDR3s with zero, one, two or more positive charges. The absolute number of clones analyzed in each B cell fraction is indicated in the center. A one-tailed, two-proportion z-test was performed considering the non-autoreactive and ANA-reactive groups as two independent samples. Zero positive charges, $p = \text{n.s.}$; one positive charge, $p = \text{n.s.}$; two or more positive charges, $p < 0.05^*$. The average number of positively charged residues per CDR3 is indicated below each fraction. **(B)** The frequency of positively charged residues (≥ 2) per heavy-chain CDR3 of the new emigrant compartment of ADA deficient patients significantly decreases postGT.




Supplemental Figure 2

ADA-deficient mature naive B cells express polyreactive antibodies before and after gene therapy. Antibodies from the mature naïve B cell fraction of **(A)** two ADA-SCID patients before and **(B)** three patients after gene therapy were tested in ELISA for reactivity with double-stranded DNA (dsDNA), insulin and lipopolysaccharide (LPS). Young adult HD27 is shown as representative control. Dotted lines show ED38-positive control. Horizontal lines show cut-off OD405 for positive reactivity. For each individual, the frequency of polyreactive (in black) and non polyreactive (in white) clones is summarized in pie charts with the number of antibodies tested indicated in the centers.





Supplemental Figure 3

Defective phosphorylation of Syk and BTK upon TLR stimulation in naive B cells after ADA and IRAK1/4 inhibition. Total PBMCs from healthy donors after ADA or IRAK1/4 inhibition were stimulated *in vitro* with F(ab')₂ anti-IgM, CpG or Gmod for 15min. **(A)** Representative histogram blots for Syk phosphorylation. **(B-D)** Fold increase of phosphorylation as compared to non-stimulated controls for **(B)** Syk, **(C)** BTK and **(D)** PLCγ2. Data are representative of at least four independent experiments; **p*≤0.05.




Supplemental Figure 4

Defective phosphorylation of ERK1/2 upon BCR stimulation in B cells after ADA inhibition. Total PBMCs from healthy donors after ADA or IRAK1/4 inhibition were stimulated *in vitro* with F(ab')₂ anti-IgM, CpG or Gardiquimod for 15min. **(A)** Representative histogram blots for ERK1/2 phosphorylation in naïve B cells (left) and memory B cells (right) after F(ab')₂ anti-IgM stimulation. **(B)** Fold increase of phosphorylation as compared to non-stimulated controls for ERK1/2. Data are representative of three independent experiments; **p*<0.05.




Supplemental Figure 5

Defective TLR-induced upregulation of B cell activation markers after ADA inhibition. Naive B cells from healthy donors after ADA inhibition with increasing concentrations of EHNA were stimulated in vitro with Gardiquimod (TLR7 agonist), CpG (TLR9 agonist) or F(ab')₂ anti-IgM for 2 days. **(A)** Representative dot plots, **(B)** percentages and mean fluorescence intensity (MFI) for CD25 and CD69. Data are representative of at least three independent experiments.



Supplemental Figure 6

Defective TLR-induced upregulation of B-cell activation markers after stimulation in the presence of 2-chloroadenosine (cAdo). **(A)** Dot plots show CD25 and CD69 expression on naïve B cells from healthy donors exposed to increasing concentrations of cAdo and stimulated or not (NS) *in vitro* with Gardiquimod (TLR7 agonist), CpG (TLR9 agonist) or F(ab')₂ anti-IgM for 2 days. Percentages and mean fluorescence intensity (MFI) for CD25 and CD69 are shown in **(B)**. Data are representative of at least six independent experiments \pm SEM.



Supplemental Figure 7

The majority of ANA expressing B cell clones found in the postGT fractions of ADA-SCID patients are not gene-corrected. **(A)** Overall frequency of gene-corrected (NeoR+) and not gene-corrected (NeoR-) B cells in the new emigrant B-cell compartment of ADA-SCID patients 1-3. **(B)** The frequency of anti-nuclear new emigrant B cells in ADA-deficient patients is completely corrected after gene therapy and is comparable to controls. Average is shown as bar +SEM; * $p=0.05-0.005$; n.s.= not significant. **(C)** Overall frequency of gene-corrected (NeoR+) and not gene-corrected (NeoR-) B cells in the mature naïve B-cell compartment of ADA-SCID patients 1-3. **(D)** The frequency of anti-nuclear mature naïve B cells in ADA-deficient patients after gene therapy is comparable to controls. Average is shown as bar +SEM; * $p=0.05-0.005$; n.s.= not significant. When separating gene-corrected (NeoR+) from non-corrected (NeoR-) within the new emigrant and mature naïve B cells postGT the NeoR- fraction contains most ANA expressing clones.

Supplemental Table 1: Repertoire and reactivity of antibodies from new emigrant B cells of HD27

Ig	HEAVY					LIGHT					REACTIVITY	
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	Staining
neHD27 01	3-23	/	/	5	DSSFDFWDFP	9	1-8	1	QQYYSYPRT	9	-	-
neHD27 05	4-39	4-17	2	4	DPNYGFSFDY	10	1-6	4	LQDYNYPPT	9	-	-
neHD27 06	3-23	3-22	3	1	GAPSGIVVVITLYFQH	16	4-1	4	QQYYSTPLT	9	-	-
neHD27 07	3-23	3-3	3	6	LGEIFGVVIIGGMDV	15	1-9	4	QQLNSYFLT	9	-	-
neHD27 08	3-7	4-17	2	3	DRITYGRPDAFDI	13	1-5	4	QQYNSYSRLT	10	-	-
neHD27 09	4-39	1-26	2	6	VGGSSLHYYYGMDV	15	1-39	4	QQSYSTLALT	10	-	+ (C)
neHD27 10	4-39	6-13	3	4	RPRIAAAGGGYFDY	14	3-15	2	QQYNNWPQD	9	-	-
neHD27 11	4-31	3-10	1	3	ELGFGEVPDAFDI	13	1D-8	1	QQYYSFPRT	9	-	+ (C)
neHD27 13	3-21	6-13	3	4	GTTLGIAAAGSTVLGYFDY	19	3-15	1	QQYNNWPRT	9	-	+ (C)
neHD27 15#	3-30	2-2	3	6	DRGDIVVPAAIRYYYYGMDV	21	2-29	5	MQSIQPPIT	9		
neHD27 16	3-30	6-19	3	5	DPSIAVAGTWWFDP	14	1-12	3	QQANSFPPS	9	-	-
neHD27 18	4-59	/	/	4	DSDS	4	1-39	2	QQSYSTPRT	9	-	-
neHD27 19	4-34	1-26	3	6	GGATRPAPMDV	11	1-8	2	QQYYSYPHT	9	-	-
neHD27 20	4-59	2-2	3	6	VAYGFQVPAAIRYYMDV	19	1-39	4	QQSYSTPLT	9	+	-
neHD27 23	3-64	2-2	3	4	DHHIVVPAAPI	12	2-28	1	MQALQTPRT	9	-	-
neHD27 24	4-39	3-16	2	4	ATWGGSGGSYRAYFDY	17	3-20	3	QQYGSPPHT	9	-	-
neHD27 25	4-4	/	/	4	RNGAFHY	7	1-5	2	QQYNSYSYT	9	-	-
neHD27 26	3-7	6-19	3	4	DKVPIAVPNDY	12	1-9	1	QQLNSYPPRT	10	-	-
neHD27 27#	4-4	3-3	3	6	GPHTIFGVPRDRYYYYYMDV	22	3-11	4	QQRSNWPLPT	10		
neHD27 28	6-1	6-19	2	4	APEYSSGYDY	10	4-1	1	QQYYSTPPWT	10	-	-
neHD27 32	1-24	6-6	2	4	DPPSSSGYDY	10	3-11	1	QQRSNWPPPT	9	-	-
neHD27 33#					see lambda		3-20	2	QQYGSPPPT	10		
neHD27 35	3-7	6-19	3	3	GAAVAGHNGAFDI	13	1-8	1	QQYYSYPQT	9	-	-
neHD27 36	4-4	3-22	2	4	LRTYYYDSSGLPNQHYFDY	20	3-15	1	QQYNNWPRT	9	-	-
neHD27 39	3-30	1-7	3	4	DGRTGTTLGPFDY	13	3-20	1	QQYGSPPRT	9	-	-
neHD27 45#	3-15	3-22	2	2	DRGIEVSGYPPHAFDI	17	3-11	5	QQRSNWPPIT	10		
neHD27 46	3-3-	3-3	2	4	GALPDFWSGYSLDYFDY	17	3-15	1	QQYNNWPPWT	10	-	-
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Staining
neHD27 02	4-34	3-9	2	5	GGYDILTGYGNWFDP	15	1-40	3	QSYDSSLGSRV	12	-	-
neHD27 04	4-59	3-10	2	6	MGHYGSYSYNTGDMDV	18	2-14	2	SSYTSSSTVV	10	-	-
neHD27 09					see kappa		1-51	3	GTWDSLSAWV	11	-	-
neHD27 12	4-34	3-22	3	5	ALTMIVVGNWFDP	13	1-40	2	QSYDSSLGGSV	11	-	-
neHD27 14	1-69	5-24	3	4	AVEMATIRYFDY	12	8-61	3	VLYMGSGIWW	10	+	-
neHD27 17	3-23	/	/	4	DRGIVTFRTFDY	12	2-14	1	SSYTSSSTPGSV	12	-	+ (C)
neHD27 21	3-43	6-13	3	4	AGGIAAASAGGFYDY	14	3-21	1	QWWDSSSDHYV	11	-	-
neHD27 22	4-61	6-13	3	6	DLGTAADYYYYYGMDV	17	2-14	1	SSYTSSFYV	9	-	-
neHD27 28					see kappa		2-11	3	CSYAGSYWV	9	-	-
neHD27 29	3-13	1-26	2	2	GREYSGSYWYFDL	14	6-57	2	QSYDSSNHVV	10	-	-
neHD27 30	3-15	5-24	2	2	GRDGYNGGLTGHWFYDL	17	2-23	2	CSYAGSSTSVV	11	-	-
neHD27 31	3-21	4-17	3	5	DYTVTTGGWFDP	12	3-1	2	QAWDSSSTAWDVV	12	-	-
neHD27 33#	4-61	1-26	2	1	YSGSYFEYFQH	11	3-1	2	QAWDSSSTVV	9		
neHD27 38	3-30	6-13	3	4	GGGIAAAGKRGVLWY	15	2-14	2	SSYTSSSIVV	10	-	-
neHD27 41	3-30	6-13	3	6	DQTSYIAAAHYYYYYGMDV	19	1-44	3	AAWDDSLNGLV	11	-	+ (F)
neHD27 42	3-30	5-5	3	6	APSRTAMVVGMDV	13	8-61	3	VLYMGSGIWW	10	-	-
neHD27 43	3-23	3-10	1	4	AQGFCELLSLSYFDY	15	1-40	3	QSYDSSLGGSWV	12	-	-
neHD27 44	3-33	3-10	2	6	DHLYGSGSYNNENYYYYYGMDV	22	1-44	1	AAWDDSLNGYV	11	-	-
neHD27 47	3-33	6-19	2	4	DLRHSGWYLDYSY	12	2-14	2	SSYTSSSTVV	10	-	-
neHD27 48	4-39	3-22	2	4	RGYYDSSGYKFDY	13	2-14	3	SSYTSSSPWV	10	-	-
	VH	D	RF	JH	CDR3 (aa)	Length						
neHD27 40	4-59	3-22	2	6	GVSLDSSGYLDPYYMDV	18						
neHD27 37	1-69	3-22	2	4	DQPYYYDSSGRTNLFYD	17						

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 2: Repertoire and reactivity of antibodies from new emigrant B cells of HD28

Ig	HEAVY					LIGHT					REACTIVITY	
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	Staining
neHD28 1#	1-69	2-15	3	5	DRVVAATRGEFDP	14	1-39	2	QQSYSTPCS	9		
neHD28 2	1-24	3-16	2	3	ANPWGSYRSHAFDI	14	3-11	4	QQRSNWPLT	9	-	-
neHD28 3#	1-69	3-22	2	6	VLYDSSGSFYYYGMDV	18	1-27	1	QKYNSAPWT	9		
neHD28 4	3-30	3-22	2	4	ELGDHYDSSGYQRTPFDY	19	3-15	3	QQYNNWPPLFT	11	-	-
neHD28 6	3-30-3	1-26	2	3	GVASYYGGAFDI	12	1-8	2	QQYYSYPYT	9	-	+(F)
neHD28 7#	3-23	3-22	2	4	GAYYYDSSGYRWPFDY	17	1-8	2	QQYYSYLYT	9		
neHD28 8	3-21	5-12	2	1	VFDHTNPTEGYSYGEYFQH	20	1-5	2	QQYNSYPCS	9	-	-
neHD28 11	4-59	6-13	1	6	DRGIVKQLVRVGYYYGMDV	21	3-11	2	QQRSNWLYT	9	+	+(F)
neHD28 17	1-2	2-2	2	5	DFWDRGDGPGYCSSTSCYTSSPPRMIFDP	29	1-39	1	QQSYSTPWT	9	-	-
neHD28 18	3-33	3-22	2	1	GRYYYDSSGYGYYGEYFQH	18	4-1	1	QQYYSTPPT	9	-	-
neHD28 20#	1-8	/	/	6	KRDYYYGMDV	10	1-39	2	QQSYSTPYT	9		
neHD28 24#	4-34	6-13	3	1	GLGAAGPVHQH	11	4-1	2	QQYYSTPPG	9		
neHD28 25	4-59	6-19	3	5	HGREAGTP	8	4-1	5	QQYYSTLIT	9	-	+(C)
neHD28 26	4-31	3-10	2	4	GLWYYGSGSYKQFDY	16	1-12	5	QQANSFPIT	9	+	-
neHD28 28	4-39	3-22	2	3	RYYYDSSGYLRDAFDI	16	1-6	1	LQDYNYPWT	9	-	-
neHD28 31	3-33	/	/	6	VRVPNYYYGMDV	13	2-28	1	MQALQTPWT	9	-	-
neHD28 33	3-15	4-17	3	3	DRGLTTVTDAFDI	14	2-28	2	MQALQTPPS	9	-	-
neHD28 34	1-18	3-10	2	6	DRPYGSSYDLYYYYGMDV	19	3-20	1	QQYGSSPQT	9	-	+(C)
neHD28 36	3-21	/	/	4	GPGSFQVDY	9	1-39	4	QQSYSTPALT	10	+	+(C)
neHD28 41	4-59	5-24	2	3	LMATGKDAFDI	11	1-8	2	QQYYSFPYT	9	-	-
neHD28 44	1-2	6-19	2	6	ASSSGWYNYGMDV	14	1-16	2	QQYNSYPYT	9	-	-
neHD28 45#	1-18	3-3	2	3	GAGSMSYDFWSGY	13	4-1	1	QQYYSTPQT	9		
neHD28 46	4-31	2-15	3	5	EVVVAAMKNWFDP	13	1-39	1	QQSYSTPRT	9	-	-
neHD28 5#							4-1	2	QQYSTPCS	9		
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Staining
neHD28 12	3-73	3-22	2	6	RVDDSSGYTNYYYGMDV	17	3-1	2	QAWDSSIVV	9	-	-
neHD28 14	4-34	4-17	3	4	GRSYLPTVTYYFDY	15	3-21	1	QVWDSSTDHYV	11	-	-
neHD28 15#	5-51	/	/	2	HRYFDL	6	2-8	3	SSYAGSNK	8		
neHD28 19#	1-18	1-1	2	4	DRATAVTNWSYD	12	2-14	3	SSYTSSTRV	10		
neHD28 29	3-33	5-5	3	4	VDTAMGTKGKEKTFDY	16	1-44	3	AAWDDSLNGWV	11	-	-
neHD28 30	3-23	2-21	2	4	EGTYCGGDCYSGHFDY	16	3-21	2	QVWDSSTDHVV	11	-	-
neHD28 32#	1-18	3-10		4	HLSIGFGSDYFDY	13	1-40	3	QSYDSSLSEGV	11		
neHD28 34					see kappa		3-21	3	QVWDSSTDHWV	11	-	+(C)
neHD28 35	1-2	3-3	1	5	VLEGAAPWGTLE	12	1-47	1	AAWDDSLSGYV	11	-	-
neHD28 36					see kappa		2-14	1	SSYTSSTPYV	11	-	-
neHD28 39	3-21	6-19	2	4	DLWDAGYSSGWYQVGYGYFDY	22	1-44	1	AAWDDSLNGYV	11	-	-
neHD28 40	1-2	2-8	2	6	GYKCTNGVCTYDGMVDV	16	3-21	1	QVWDSSTDHYV	11	-	-
neHD28 41					see kappa		2-11	1	CSYAGSYTVYV	11	-	-
neHD28 43	4-4	1-20	3	6	VWGTGTTYGMDV	12	1-44	1	AAWDDSLNGLYV	12	-	-
neHD28 47	4-31	3-22	2	4	AAGNYDSSGYHYFDY	16	2-14	2	SSYTSSTTVV	10	-	-

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 3: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 1 before gene therapy

Ig	HEAVY						LIGHT				REACTIVITY	
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	Staining
neADA1-pre 01	3-7	7-27	3	3	DPSTGGHDAFDI	12	3-11	2	QQRSNWSGPLCS	12	-	-
neADA1-pre 02	1-2	3-10	2	4	PLGSGSYNY	9	3-20	1	QQYGSSPWT	9	-	-
neADA1-pre 03	1-3	6-19	3	4	LAVAGTPFDY	10	1-39	2	QQSYSTPYT	9	-	-
neADA1-pre 04	3-7	2-15	2	4	GYCNGGSCPYYFDY	14	1-16	1	QQYNSYPRQSLMT	13	+	+(C)
neADA1-pre 06	3-9	6-6	3	3	DRAAARPLRYAFDI	14	1-5	4	QQYNSYPT	8	-	-
neADA1-pre 08#	3-21	2-15	3	6	EDIVVVVAATPFRDMDV	17	1-39	5	QQSYSTLT	8		
neADA1-pre 09	3-15	3-3	1	4	HSPKQLQLEWFCDY	14	3-20	2	QQYGSSPCS	9	+	+(N)
neADA1-pre 10	4-59	6-13	3	4	HGIAAVWSPFDY	12	1-8	1	QQYYSYPWT	9	+	+(C)
neADA1-pre 12	3-30-3	/	/	3	AQRGDAFDI	9	1-39	2	QQSYSTPYT	9	-	-
neADA1-pre 13#	3-15	3-10	3	4	EPLKKTGKGVIIKGDY	16	3-11	4	QQRSNWPSLT	10		
neADA1-pre 14#	4-34	6-6	3	4	RYAARPYFDY	11	1-33	5	QQYDNLPT	9		
neADA1-pre 15	3-66	6-19	2	4	DLVSGSGWDY	10	3-20	1	QQYGSLLWT	9	-	-
neADA1-pre 16	3-11	3-3	2	4	VYDFWFSFY	9	2-30	4	MQGTHWPPLT	10	-	-
neADA1-pre 18	3-15	3-22	2	4	DSDDSSGGYGYFDY	14	2-28	3	MQALQTFT	8	-	-
neADA1-pre 19#	3-11	3-3	1	4	GNLRFLEWLSYFDY	14	3-20	1	QQYGSLLWT	9		
neADA1-pre 22	3-43	1-7	3	4	QTGTGLDY	8	1-39	4	QQSYSTPLT	9	-	-
neADA1-pre 23	3-15	6-13	1	4	DLQQLPRRYFDY	13	1-6	3	LQDYNYPFT	9	+	-
neADA1-pre 24	4-39	2-21	2	4	YCGGDCVYVYFDY	12	3-20	2	QQYGSSPYT	9	+	+(C)
neADA1-pre 26	3-30	6-19	3	3	DIAVADHDAFDI	12	1-8	3	QQYYSYPFT	9	-	+(C)
neADA1-pre 27	3-9	3-9	2	4	GRHRYDILTGYRDY	14	1-33	3	QQHDNLPT	9	+	-
neADA1-pre 28#	3-11	3-10	3	4	GPITMVQG	8	3-15	4	QQYNNWPPNLT	11		
neADA1-pre 31#	1-3	6-13	3	4	DPLVGIAAAGSGY	13	3-20	4	QQYGSSPV	8		
neADA1-pre 33	3-23	2-15	2	3	FYCSCGGSCYRDAFDI	15	2-30	4	MQGTHWP	8	-	+(S)
neADA1-pre 34	3-23	1-20	2	4	RRYNWNDEEQVY	12	3-20	2	QQYGSSPCS	9	+	+(N)
neADA1-pre 35	5-51	/	/	4	FRTYVYFDY	8	1-12	4	QQANSFPLT	9	-	-
neADA1-pre 39#	4-34	4-23	3	4	TVEHYVYFDY	9	3-15	2	QQYNNWPRFRFRYT	14		
neADA1-pre 40#	4-34	6-13	2	3	PCRYSSIQDAFDI	13	1-17	2	LQHNSYPRS	9		
neADA1-pre 41	3-30-3	6-13	1	5	ASLRQQLVGGWFDP	14	3-15	4	QQYNNWPPPLT	10	-	-
neADA1-pre 45	3-30-3	6-13	2	1	VQGSSWYLVGYFQH	13	1-17	4	LQHNSYPPT	9	+	+(N)
neADA1-pre 46	3-30-3	6-19	3	2	DARIAVADPYWYFDL	15	1-8	4	QQYYSYPLLT	10	+	+(N)
neADA1-pre 48	3-9	/	/	4	VGRERSGFY	10	1-39	2	QQSYSTLMCS	10	-	-
neADA1-pre 05							3-20	2	QQYGSSPFSCS	11		
neADA1-pre 07							1-27	3	QKYNSALPIT	10		
neADA1-pre 11							1-39	4	QQSYSTPLT	9		
neADA1-pre 17							1-33	3	QQHDNLPLT	9		
neADA1-pre 21							3-15	1	QQYNNWPPWT	10		
neADA1-pre 25							1-9	4	QQLNSYPLT	9		
neADA1-pre 29							4-1	5	QQYYSTIT	8		
neADA1-pre 32							3-11	1	QQRSNWPWT	9		
neADA1-pre 36							1-27	2	QKYNSAPHT	9		
neADA1-pre 37							3-15	1	QQYNNWPPWT	10		
neADA1-pre 38							2-29	3	MQGIHLPT	9		
neADA1-pre 43							2-30	1	MQGTHWPRT	9		
neADA1-pre 44							3-11	5	QQRSNWPIT	9		
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Staining
neADA1-pre 30	3-15	/	/	2	DPNRWYFDL	9	2-23	1	CSYAGSSTFV	10	-	-
neADA1-pre 32#	1-2	/	/	4	SPEDY	5	2-23	1	CSYAGSSTYV	10		
neADA1-pre 42#	4-59	3-22	2	4	RVYDSSGYVYFDY	13	2-23	1	CSYAGSSTYV	10		
neADA1-pre 47	4-39	3-9	1	4	DLRYFDWLLYYFDY	14	2-14	2	SSYTSSTLVV	11	+	+(C)

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 4: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 2 before gene therapy

Ig	HEAVY						LIGHT				REACTIVITY	
	VH	D	RF	JH	CDR3 (aa)	Length	Vk	Jk	CDR3 (aa)	Length	Poly	Staining
neADA2-pre 02	3-7	6-19	2	4	AGYSSAGY	8	1-5	2	QQYNSYSMYT	10	-	+ (N)
neADA2-pre 03#	3-21	2-2	3	6	DVLVVPAAAMDV	11	1-8	2	QQYYSYPRT	9		
neADA2-pre 07	1-8	6-13	3	2	RAAARSYWYFDL	12	1-5	1	QQYNSYPWT	9	+	+ (C)
neADA2-pre 09	3-48	1-26	3	5	LVGAMGTYWFDP	12	3-20	2	QQYGSSPPYT	10	-	-
neADA2-pre 11	3-15	1-26	3	4	EVGASQY	7	3-11	2	QQRNNT	6	-	-
neADA2-pre 24	1-18	6-19	3	5	VLGIAVAGTSWFDP	14	1-39	3	QQSYSTLT	8	-	-
neADA2-pre 28	3-53	2-15	2	4	MSGYCSGGSCLLM	13	1-5	2	QQYNSYLYT	9	+	-
neADA2-pre 30	3-30	3-10	2	4	STKSQSGSGSYNVRRYFDP	19	3-15	2	QQYNNWPPYT	10	+	+ (N)
neADA2-pre 43#	1-2	2-2	3	5	LKGIVVPAaipNNWFDP	18	1D-17	3	LQHNSYPFT	9		
neADA2-pre 103#	3-23	3-10	1	4	VLGENWLDY	9	1-8	2	QQYYSYPRT	9		
neADA2-pre 202	3-30-3	3-16	2	4	EGYYDYVWGSYRPFYFDY	18	1-5	4	QQYNSYPLT	9	-	-
neADA2-pre 204	4-4	/	/	5	AEVDWGYIEVGWFDV	15	3-15	2	QQYNNWPRT	9	-	-
neADA2-pre 205	4-59	5-5	2	6	SGYSYGYRLHGMDV	14	1-39	2	QQSYSTPHT	9	+	+ (C)
neADA2-pre 207	3-21	6-19	3	4	DRTTGIAVASDY	12	3-11	2	QQRSNWPQT	9	-	-
neADA2-pre 209	4-4	2-8	2	4	TVSTNGELNFDY	12	1-8	1	QQYYSYPRT	9	-	+ (N)
neADA2-pre 211#	3-15	6-6	3	4	DLAARRCFDY	10	1D-12	1	QQANS	5		
neADA2-pre 215	4-59	6-19	3	4	VNGGAGKLDY	11	2-28	1	MQALQTPWT	9	-	-
neADA2-pre 216	3-30	6-6	2	4	EPFLPRYSSHVLGYFDY	17	4-1	2	QQYYSMYT	8	-	-
neADA2-pre 219	5-51	2-2	2	4	HGGYCSSTSCQYSPFDY	17	3-20	1	QQYGSSPRT	9	-	-
neADA2-pre 221	4-34	2-2	3	4	RRIVVPAAKENFDY	15	3-15	1	QQYNNWPRT	9	-	-
neADA2-pre 222	1-18	6-19	3	4	GRIAVAGTFDY	11	1-5	4	QQYNSYPLT	9	-	-
neADA2-pre 225	3-30-3	1-26	1	1	GVIRWELLILAGEYFQH	17	3-15	1	QQYNNWPPWT	10	+	+ (N)
neADA2-pre 227	3-9	6-6	2	4	RYSSSEFDY	10	3-15	3	QQYNNWPG	8	-	-
neADA2-pre 231	3-21	3-22	2	4	DHLNRDYYDSSGKYHYFDY	19	1-39	2	QQSYSTPYT	9	-	-
neADA2-pre 232	1-2	5-5	3	4	GSDTAMVPGTYYFDY	15	3-11	1	QQRSNWT	7	-	-
neADA2-pre 233#	4-34	6-13	3	4	GIAAAGTRILIPKRRHLVRLDY	25	3-20	1	QQYGSSPPWT	10		
neADA2-pre 234#	3-15	2-2	2	6	RCSSTSCYLNYYYGMDV	17	1-33	2	QQYDNLPMYT	10	+	-
neADA2-pre 236#	3-9	1-26	3	4	DRGLGANLDYFDY	13	3-20	2	QQYGSSPYT	9		
neADA2-pre 246	3-30	4-17	2	4	DYGTMAYYFDY	11	3D-20	5	QQYGSSPIT	9	-	-
neADA2-pre 05							1-39	2	QQSYSTPYT	9		
neADA2-pre 06							2-28	1	MQALQTPPWT	10		
neADA2-pre 14							1-27	4	QKYNAPLT	9		
neADA2-pre 20							3-15	2	QQYNNWPPTYT	11		
neADA2-pre 26							4-1	2	QQYSTPYT	9		
neADA2-pre 34							3-15	1	QQYNNWPRT	9		
neADA2-pre 37							1-39	3	QQSYSTPFT	9		
neADA2-pre 40							1-5	2	QQYNSYPYT	9		
neADA2-pre 210							3-20	1	QQYGSSPRT	9		
neADA2-pre 213							1-5	5	QQYNSYSKT	9		
neADA2-pre 218							1-39	3	QQSYSTPLFT	10		
neADA2-pre 220							2-28	5	MQALQTPIT	9		
neADA2-pre 224							2-28	4	MQALQTLPH	10		
neADA2-pre 239							4-1	2	QQYSTPMYT	10		
neADA2-pre 241							3-20	3	QQYGSSRFT	9		
neADA2-pre 242							1-39	3	QQSYSTPFT	9		
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Staining
neADA2-pre 131	3-43	6-13	3	4	DILQGAGSCFDY	12	2-23	2	CSYAGSSTFVV	11	-	-
neADA2-pre 217	3-30	6-13	3	4	GGVAAAGRDSSGSPWPFYFDY	22	2-23	1	CSYAGSSTYV	10	-	-
neADA2-pre 226#	3-30	/	/	4	GRLALRGIDY	10	3-21	3	QVWDSSSDHWV	11		
neADA2-pre 228	3-23	3-22	2	6	AGLDSSGSKLRYYYYGMDV	20	3-1	2	QAWDSSSTVV	9	-	+ (N)
neADA2-pre 230#	1-8	3-22	3	3	GAGAVEVVITFDI	14	3-21	2	QVWDSSSDHWV	11		
neADA2-pre 237	3-43	6-6	2	6	DMRGREDSSSLRDGYYYGMDV	21	1-47	2	AAWDDSLSGPV	11	-	-
neADA2-pre 241	3-30	3-22	3	6	GFFLSMIVVMGMDV	16	2-14	2	SSYTSSTLVV	11	+	+ (C)
neADA2-pre 245							1-51	1	GTWDSLSAFYV	12		
neADA2-pre 233							2-14	2	SSYTSSTHVV	11		
neADA2-pre 240							2-23	1	CSYAGSSTSHYV	12		
	VH	D	RF	JH	CDR3 (aa)	Length						
neADA2-pre 41	1-8	6-6	2	4	GPYSSLDY	8						
neADA2-pre 47	1-2	6-19	2	4	YEDSSGLGY	9						
neADA2-pre 122	1-2	2-15	2	5	GDCSGGKRVMLNWFDP	18						
neADA2-pre 203	3-30	5-24	3	4	IKGGATILADYFDY	14						
neADA2-pre 235	3-7	4-17	2	6	DSGDYLDShYYYGMDV	17						

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 5: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 3 before gene therapy

Ig	HEAVY					Length	LIGHT				REACTIVITY	
	VH	D	RF	JH	CDR3 (aa)		Vk	Jk	CDR3 (aa)	Length	Poly	Staining
neADA3-pre 01	3-30	2-2	2	6	APYCSSTSCLRRLLDYYGGMDV	21	3-11	4	QQRSNWPLT	10	-	-
neADA3-pre 02	3-48	6-6	2	4	DRDRYSSSSGDY	12	1-39	2	QQSYSTPYS	9	-	+ (N)
neADA3-pre 03#	4-59	6-19	3	5	DRGAVAGTVENWFDP	15	4-1	1	QQYYSTPPT	9		
neADA3-pre 05	1-69	/	/	6	DRGLGGYYYGMDV	13	1-NL1	2	QQYYSTPAS	9	+	-
neADA3-pre 06	3-49	5-12	3	4	EGGGRVVALRY	11	1-5	1	QQYNSYSWT	9	+	+ (C+N)
neADA3-pre 16	3-9	3-3	1	4	QPAFLEWSFFDY	12	3-20	4	QQYGSSPST	9	-	+ (C+N)
neADA3-pre 18	3-7	3-22	2	4	SIECFHYDSSGYRHFYD	19	2-29	3	MQGIHLPT	9	+	-
neADA3-pre 20	3-11	2-2	2	6	SSLWRGYCSSTSCYASYGMDV	21	2-28	2	MQALQTPYT	9	-	-
neADA3-pre 21	1-18	6-13	2	3	ANRGPYSSSWPGDAFDI	17	1-8	1	QQYYSPPT	9	-	-
neADA3-pre 22	3-48	5-5	1	4	DLVQLWPFYD	10	3-15	1	QQYNNWPPWT	10	-	-
neADA3-pre 23	4-39	6-19	3	6	VCIAVAGHYYYYGMDV	17	3-11	2	QQRSNWPPYT	10	+	+ (C)
neADA3-pre 25	3-66	4-23	2	6	DGGNSEYYYGMDV	14	1-8	1	QQYYSPWT	9	-	+ (C)
neADA3-pre 26	3-23	6-6	1	4	RTQQLVTDY	9	4-1	4	QQYYSTPVT	9	-	+ (C+N)
neADA3-pre 30	1-18	6-19	2	4	VSGSGWYDGY	10	3-20	1	QQYGSSPVT	9	-	-
neADA3-pre 38	3-53	6-19	3	4	GGVIAVAGSFDY	12	1D-8	1	QQYYSFPWT	9	-	+ (C+N)
neADA3-pre 43#	1-69	3-10	2	5	DRYYGSGTLYNWFDP	15	1D-43	4	QQYYSTPRLT	10		
neADA3-pre 44	3-15	/	/	3	DPYAPYDI	8	1-8	2	QQYYSPYS	9	-	-
neADA3-pre 46	4-b	3-22	2	4	HTYYDSSGYPFYD	14	1-39	1	QQSYSTLTWT	10	+	+ (C+N)
neADA3-pre 13							1-5	1	QQYNSYPWT	9		
neADA3-pre 14							3-11	2	QQRSNWPPYT	10		
neADA3-pre 17							1-39	2	QQSYSTPYT	9		
neADA3-pre 42							3-20	1	QQYGSSLWT	9		
neADA3-pre 45							1-5	2	QQYNSYSSYT	10		
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Staining
neADA3-pre 04	1-2	6-19	1	2	DKREWLAIFYDL	12	2-14	2	SSYTSSSTLVV	11	-	+ (C)
neADA3-pre 15	3-15	3-9	2	4	DDILTGYGGDY	12	1-36	3	AAWDDSLNGWV	11	+	+ (C)
neADA3-pre 17	3-21	3-9	3	4	GLVITNGGY	9	6-57	2	QSYDSSNVV	9	-	+ (C)
neADA3-pre 25					see kappa		2-23	3	CSYAGSSRV	9	-	+ (C)
neADA3-pre 28	3-11	2-21	3	4	DRVTAMLFDY	10	3-21	2	QVWDDSSDHVV	11	-	-
neADA3-pre 35#	3-15	3-16	2	6	DTLPDYDYVWGSYKDYGMDV	20	1-47	1	AAWDDSLSGYV	11		
neADA3-pre 39	3-23	5-5	2	4	PGYSYAGDFDY	11	7-46	2	LLSYSGAVV	9	+	+ (C+N)
neADA3-pre 19							3-1	3	QAWDSSTAV	9		
neADA3-pre 34							2-8	1	SSYAGSNIGV	10		
neADA3-pre 36							1-47	2	AAWDDSLSGPV	11		
	VH	D	RF	JH	CDR3 (aa)	Length						
neADA3-pre 07	4-61	1-26	3	4	SIVGATTGVFDY	12						
neADA3-pre 08	4-61	/	/	2	QWGPVDNWFYDL	12						
neADA3-pre 11	3-23	1-26	2	4	LNHRSGSYDYLDPPQFDY	17						
neADA3-pre 33	4-39	3-10	1	4	HPLAWFDRSFDY	12						
neADA3-pre 37	3-15	1-26	2	4	GYSGSYKY	9						

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 6: Repertoire and reactivity of ANA-expressing B cell clones from ADA-SCID patients 1-3 before and after gene therapy

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	Hep-2 staining	Chromatin	Crithidia staining
neADA1-pre 09	3-15	3-3	1	4	HSPKLFLEWFCDY	14	3-20	2	QQYGSSPCS	9	+ (N)	-	-
neADA1-pre 33	3-23	2-15	2	3	FCYCSGGSCYRDAFDI	15	2-30	4	MQGTHWPT	8	+ (S)	-	-
neADA1-pre 34	3-23	1-20	2	4	RRYNWNDEEQVY	12	3-20	2	QQYGSSPCS	9	+ (N)	-	-
neADA1-pre 45	3-30-3	6-13	2	1	VQGSWYLYGFQHQ	13	1-17	4	LQHNSYPPT	9	+ (N)	+	+ (K)
neADA1-pre 46	3-30-3	6-19	3	2	DARIAVADPYWYFDL	15	1-8	4	QQYYSYPLLT	10	+ (N)	-	-
neADA2-pre 02	3-7	6-19	2	4	AGYSSAGY	8	1-5	2	QQYNSYSMYT	10	+ (N)	-	-
neADA2-pre 30	3-30	3-10	2	4	STKSQSGSGSYNVRRYFDP	19	3-15	2	QQYNNWPPYT	10	+ (N)	+	+ (K+N)
neADA2-pre 209	4-4	2-8	2	4	TVSTNGELNFDY	12	1-8	1	QQYYSYPRRT	9	+ (N)	-	-
neADA2-pre 225	3-30-3	1-26	1	1	GVIRWELLILAGEYFOHQ	17	3-15	1	QQYNNWPPWT	10	+ (N)	-	-
neADA3-pre 02	3-48	6-6	2	4	DRDRYSSSSGDY	12	1-39	2	QQSYSTPYS	9	+ (N)	-	-
neADA3-pre 06	3-49	5-12	3	4	EGGGRVVALRY	11	1-5	1	QQYNSYSWT	9	+ (C+N)	-	-
neADA3-pre 16	3-9	3-3	1	4	QPAFLEWSFFDY	12	3-20	4	QQYGSSPST	9	+ (C/N)	-	-
neADA3-pre 26	3-23	6-6	1	4	RTQQLVTDY	9	4-1	4	QQYYSTPVT	9	+ (C/N)	-	-
neADA3-pre 38	3-53	6-19	3	4	GGVIAVAGSFDY	12	1D-8	1	QQYYSFPWT	9	+ (C/N)	+	+ (K)
neADA3-pre 46	4-b	3-22	2	4	HTYYDSSGYPFDY	14	1-39	1	QQSYSTLTWT	10	+ (C/N)	+	-
Ig	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	Hep-2 staining	Chromatin	Crithidia staining
neADA2-pre 228	3-23	3-22	2	6	AGLDSSGSKLRYYYYYGMDV	20	3-1	2	QAWDSSTTV	9	+ (N)	-	-
neADA3-pre 39	3-23	5-5	2	4	PGYSYAGDFDY	11	7-46	2	LLSYSGAVV	9	+ (N+C)	+	+ (K)

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	Hep-2 staining	Chromatin	Crithidia staining
mADA2-pre 57	3-30	3-3	3	4	GEGRITIFGVVILGLIDY	19	2D-29	1	MQSIQRWT	8	+ (N)	-	-
mADA2-pre 71	3-30	2-2	2	4	GRYCSSTSCYLDY	13	1-5	1	QQYNSYPWT	9	+ (N)	-	-
mADA2-pre 85	3-30	6-19	3	4	GEVRAVAGSSC	11	1-5	1	QQYNSYSWT	9	+ (N)	-	-
mADA2-pre 252	3-64	3-3	2	4	GRYDFWSGYQY	11	1-16	2	QQYNSYPYT	9	+ (N)	-	-
mADA2-pre 259	4-34	6-6	3	4	GKGTTAARRSKETGGYFYDY	20	1-39	1	QQYSIPRT	9	+ (N)	+	+ (K)
mADA2-pre 274	4-31	3-10	2	4	EAYYSGSKQQYSNFDY	17	4-1	1	QQYYSTPRT	9	+ (N)	-	-
mADA2-pre 278	3-21	3-10	3	4	DLWLVRGVIDW	11	3-15	1	QQYNNWPPWT	9	+ (N)	-	-
mADA3-pre 67	4-31	/	/	5	DRTRNNWFDP	10	1-33	4	QQYDNLPLT	9	+ (C/N)	-	-
mADA3-pre 71	3-33	2-2	3	4	DTGVVPAAYFDY	12	1-27	3	QKYNAPFT	9	+ (C/N)	-	-
mADA3-pre 79	3-53	3-22	2	4	LYDSSGYYPFDY	12	1-39	2	QQSYSTPPYT	10	+ (N)	-	-
mADA3-pre 87	3-33	3-3	1	5	GGVQWFHP	8	2-30	4	MQGTHWPLT	9	+ (C/N)	-	-
mADA3-pre 92	1-2	1-26	3	4	DHGWGIVGAMVY	12	3-15	1	QQYNNWPPWT	10	+ (N)	-	-
mADA3-pre 95	3-30	1-26	1	4	GELLY	6	3-15	4	QQYNNWPPLT	10	+ (C/N)	+	+ (K)
Ig	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	Hep-2 staining	Chromatin	Crithidia staining
mADA2-pre 293	3-7	6-6	3	4	GGARRCDY	8	2-8	2	SSYAGSNNFVV	11	+ (N)	+	+ (N+K)
mADA3-pre 52	5-51	3-10	3	6	QDRITMVRGVITYYYYYGMDV	21	1-51	3	GTWDSLSAGV	11	+ (C/N)	+	+ (K)
mADA3-pre 96	3-21	2-21	2	6	CGGDCYSDDYGGMDV	14	3-25	1	QSADSSGTIV	10	+ (N)	-	-

Ig	HEAVY						LIGHT				GT	REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	NeoR	Hep-2 staining	Chromatin	Crithidia staining
neADA2-post 215	4-4	6-19	3	6	DLTAVAGTYGGMDV	14	3-11	2	QQRSNWPPYT	10	-	+ (N)	+	-

Ig	HEAVY						LIGHT				GT	REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	NeoR	Hep-2 staining	Chromatin	Crithidia staining
mADA2-post 287	3-33	2-2	2	6	DMGYCSSTSCLVKLYYYGMDV	24	1-39	3	QQSYSTPFT	9	+	+ (C/N)	-	-
mADA3-post 61	6-1	6-19	1	4	EPKPKSQWLHVHGAIDY	16	1-39	1	QQSYSTPWT	9	-	+ (N)	+	+ (N+K)
Ig	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	NeoR	Hep-2 staining	Chromatin	Crithidia staining
mADA3-post 51	1-2	6-13	3	4	IHLKISAAGSKSFYDY	17	3-21	2	QVWVSSSDHVV	12	-	+ (C/N)	-	-

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; K, kinetoplast

Supplemental Table 7: Repertoire and reactivity of antibodies from mature naive B cells of HD27

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	Hep2	Staining
mHD27 04	3-33	6-13	2	4	VGGWSSSWYGADY	13	2-28	4	MQALQTPLT	9	-	-	-
mHD27 06#	3-48	2-21	3	4	DHIVVVTSYFYDY	13	1-9	1	QLNSYPRT	9			
mHD27 11#	1-46	5-5	2	6	GEEYSYGYRNYYYYMDV	18	1-39	4	QSYSNPLT	9			
mHD27 19#	3-23	3-22	2	6	DRGFRYDSSPKRDYYYYMDV	19	3-15	4	QQYNNWPLT	9			
mHD27 23	4-39	3-3	3	5	ITSTIFGVRDRFDP	14	1-39	2	QSYSSTPS	8	-	+	+
mHD27 26	3-66	1-7	3	6	GTRSDYYYGMDV	12	2-40	2	MQRIEFPYT	9	-	-	-
mHD27 28	3-48	2-2	1	4	RGDQLLDWTSAFDY	14	1D-39	5	QSYSTPSIT	10	-	-	-
mHD27 29	1-18	4-4	2	5	TPYYSNPDGWFDP	13	4-1	1	QQYYSTPGT	9	-	-	-
mHD27 30	3-64	5-24	2	4	GPSRDGYNPDY	11	3-15	4	QQYNNWPPLT	10	-	-	-
mHD27 31#	3-30	3-22	3	3	DRVRIVVIRWAFDI	15	1-33	4	QQYDNLPF	8			
mHD27 33	4-34	1-7	2	5	AFTVIYNWNYGWFDP	15	3-20	4	QQYGSST	8	-	-	-
mHD27 39#	3-48	2-15	2	3	DSPSGVGLCSGGSCYLDAFDI	21	3-20	2	QQYGT	5			
mHD27 42	3-23	2-2	2	4	GLGYCSSTSCPLH	13	1-27	4	QKYNAPLT	9	-	-	+
mHD27 44	3-30	3-10	1	3	GRTNRPFGDPAFDI	16	1-33	2	QQYDNLPT	9	-	-	-
mHD27 46	3-30	6-13	1	6	DRAAAGRLGYGYGMDV	16	1-12	3	QQANSFRT	9	-	-	+
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Hep2	Staining
mHD27 02	4-39	6-13	2	4	MPYSSRSLGY	10	2-14	1	SSYTSSTLHV	11	-	-	-
mHD27 03	3-30-3	4-4	2	6	ALQDNYYYGMDV	12	2-14	3	SSYTSSTWV	10	-	-	-
mHD27 05	3-7	4-17	2	3	GGLYGDYGNDAFDI	14	1-40	2	QSYDSSLGTV	11	-	-	-
mHD27 07	4-4	2-15	3	6	GVVVAATHWSMDV	13	6-57	3	QSYDSSNHVV	10	-	-	-
mHD27 08	4-4	6-19	3	4	SRGIAVAEYFYDY	13	1-40	1	QSYDSSLGTV	11	-	-	-
mHD27 09	4-59	2-2	3	2	HVDIVVWYFDL	11	3-1	2	QAWDSSTVV	9	-	-	-
mHD27 12	3-21	3-10	3	5	IRGAPRGWFDP	11	2-23	3	CSYAGSSV	8	+	+	-
mHD27 13	4-59	6-19	3	2	SPEIAVAGHYFDY	13	3-25	3	QSADSSGTVEV	11	-	-	-
mHD27 14	1-69	1-26	2	5	TSGSPVYWFDP	11	1-40	3	QSYDSSLGTV	11	+	-	-
mHD27 15	3-33	5-5	2	3	PRRGYSYGDAFDI	14	2-8	2	SSYAGSNLTV	10	-	-	+
mHD27 16	1-3	/	/	4	DYRRGESRKTGLAFGY	16	1-40	3	QSYDSSLGTV	11	-	+	+
mHD27 17	3-23	3-22	3	3	DRSWGRVVVITYAFDI	16	1-51	3	GTWDSLSAEV	11	-	+	+
mHD27 18#	5-a	3-10	1	4	YRVGGGFCELLSDY	14	1-44	3	AAWDDSLNGWV	11			
mHD27 20#	3-30-3	2-21	2	4	VDDGSHGAEYCGDCYQFDY	20	3-9	7	QVWDSSTAV	9			
mHD27 21	3-23	2-15	3	4	DLKDIVVVAVGDYIDY	17	2-8	2	SSYAGSNKG	9	-	-	-
mHD27 22	5-51	3-22	2	4	INYYDSNYFDY	11	3-21	2	QVWDSSDHPV	11	-	-	-
mHD27 24	3-30-3	6-19	3	6	DLHPRAVAGPYYYYYGMDV	19	3-1	2	QAWDSSNVV	9	-	-	-
	VH	D	RF	JH	CDR3 (aa)	Length							
mHD27 25#	1-46	3-22	2	6	SGVGSYYYDKGMDV	14							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 8: Repertoire and reactivity of antibodies from mature naive B cells of HD28

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	Poly	Hep2	Staining
mHD28 1#	3-66	3-10	1	4	FGFGEFLYYFDY	12	3-20	1	QQYGSSLWT	9			
mHD28 4#	4-30-4	3-22	2	4	ERGYYYDSSGYYFFDY	17	1-17	1	LQHNSYPRT	9			
mHD28 8#	3-48	3-22	2	4	DAVYYDSSGSCDY	13	3-15	1	QQYNNWPWT	9			
mHD28 10	3-49	3-22	3	3	GLTMIVGEDAFDI	13	1-39	4	QQSYSTPLT	9	-	-	-
mHD28 11	3-30-3	6-6	3	6	VHWLIAEPRGNGMDV	15	2-28	5	MQALQTPT	8	-	+	+ (C)
mHD28 12	4-39	1-26	3	4	PFLVGATPPEYYFDY	15	3-11	4	QQRSNWPLT	10	-	-	-
mHD28 14#	4-34	4-23	2	4	ITTAWGGGGYFDY	13	3-20	2	QQYGSPPMCS	11			
mHD28 16#	5-51	/	/	6	REGMRGMDV	9	2-28	1	MQALQTPPW	10			
mHD28 23#	1-46	3-10	2	4	VWENYYGSGSLNY	13	2-28	5	MQALQTPT	8			
mHD28 24#	4-39	5-5	2	4	LHSGYSYGYGVFDY	14	2-29	4	MQSIQLPLT	9			
mHD28 26	3-23	5-24	1	4	DLSRWLPERGYFFDY	15	3-15	1	QQYNNWPWT	9	-	-	-
mHD28 28#	3-33	2-2	2	3	DTVGGYCSSTSCYRGAFDI	19	1-5	1	QQYNSYPTWT	10			
mHD28 29	4-39	3-3	2	4	ASGSGYPTFDY	11	1-39	5	QQSYSTL	7	-	+	-
mHD28 33	3-30-3	4-17	2	4	GATYGDYVDY	10	3-11	4	QQRSNWPALT	10	-	-	-
mHD28 34	1-2	5-12	2	4	RGYSGYDAFDY	11	2-28	3	MQALQTPFT	9	-	-	-
mHD28 35	3-21	/	/	4	DGDDFTGEVY	10	4-1	1	QQYYSTPWT	9	-	-	-
mHD28 36	4-4	6-13	3	5	GRAAGHNWFDP	11	1-5	2	QQYNSYSPYT	10	-	-	-
mHD28 39	1-69	5-24	3	4	DREVAKGGFDY	11	4-1	4	QQYYSTPPT	9	+	+	-
mHD28 41#	3-73	4-4	2	4	HAAIYSNYVDY	11	4-1	4	QQYYSTPLT	9			
mHD28 43#	3-15	3-3	1	4	DLATELRFLETIDY	14	1D-43	5	QQYYSTL	7			
mHD28 47	5-a	3-22	2	4	LREYYDSSGYYGDDY	15	3-15	1	QQYNNWPET	9	-	+	-
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Hep2	Staining
mHD28 5	1-2	/	/	4	DRREYGIDY	9	7-43	1	LLYGGAYV	9	-	+	-
mHD28 6	3-33	3-10	1	5	GESSWFGEL	9	6-57	3	QSYDSSSWV	9	-	-	-
mHD28 13	4-31	/	/	2	RGVVWYFDL	9	2-14	2	SSYTSSTLDVV	12	-	-	-
mHD28 15#	3-30-3	2-2	2	6	NHCISTSCYRHYYYYYGMDV	20	1-51	3	GWDSLSAGGV	11			
mHD28 17	3-30	3-10	2	4	DAYGSGRVGYFDY	13	1-44	2	AAWDDSLNGVV	11	-	-	-
mHD28 18#	5-a	2-15	2	3	VDCSGGSCYSPNAFDI	16	2-23	1	CSYAGSSFYV	10			
mHD28 21	4-59	/	/	3	HNPIDAFDI	9	1-51	1	GTWDSLSAYV	11	-	-	-
mHD28 27	3-43	5-5	3	4	DIWDTAMVTGFDY	13	2-23	2	CSYAGSSPVV	10	-	-	-
mHD28 35					see kappa		3-21	3	QVWDSSTDHVV	11	-	-	-
mHD28 37	1-46	6-19	2	4	DIPGSSGWYFFDY	13	2-14	1	SSYTSSTLYV	11	-	-	-
mHD28 38	4-59	3-22	2	5	RSEYYDSWFDP	11	1-47	2	AAWDDSLSGRVV	12	-	-	-
mHD28 43					see kappa		3-1	2	QAWDSSTAV	9	-	-	-
mHD28 46	1-69	6-6	3	6	DLKAQSGVAARPAYYYGMDV	20	3-1	2	QAWDSSTGV	9	+	-	-
mHD28 48	6-1	1-7	2	6	EPYNWIPVNYGMDV	15	1-44	1	AAWDDSLNGYV	11	-	-	-
mHD28 25#							3-25	2	QSADSSGTVV	10			
	VH	D	RF	JH	CDR3 (aa)	Length							
mHD28 30#	3-30-3	6-19	3	6	VVAVAGYQDYYYGMDV	16							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 9: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 2 before gene therapy

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	Poly	Hep2	Staining
mADA2-pre 57	3-30	3-3	3	4	GEGRITIFGVIIKGLIDY	19	2D-29	1	MQSIQRWT	8	+	+	+ (N)
mADA2-pre 71	3-30	2-2	2	4	GRYCSSTSCYLIDY	13	1-5	1	QQYNSYPWT	9	-	+	+ (N)
mADA2-pre 75	3-11	4-17	2	4	DRPGDYGDYFKDYFDY	16	3-15	4	QQYNNWPLT	9	-	-	-
mADA2-pre 76	3-48	6-13	2	4	ALSSSGVYFDY	11	3-11	4	QQRSNWPPPLT	11	-	-	-
mADA2-pre 83	3-21	5-5	3	4	VLVPTDTAMTVGYFDY	17	3-15	1	QQYNNWPPWT	10	-	+	+ (C)
mADA2-pre 85	3-30	6-19	3	4	GEVRAVAGSSC	11	1-5	1	QQYNSYSWT	9	+	+	+ (N)
mADA2-pre 91#	3-23	/	/	4	SGV	3	2-24	1	MQATQFPRT	9			
mADA2-pre 252	3-64	3-3	2	4	GRYDFWGSYQY	11	1-16	2	QQYNSYPYT	9	+	+	+ (N)
mADA2-pre 253	4-59	3-10	2	4	SLPRFDTYYYGSGSYSYFDY	20	3-15	5	QQYNNWPPIT	10	+	+	-
mADA2-pre 258#	3-23	/	/	4	VDYGDY	6	3-11	1	QQRSNWPSGT	10			
mADA2-pre 259	4-34	6-6	3	4	GKGTIAARRSKETGGYYFDY	20	1-39	1	QQSYSIPRT	9	+	+	+ (N)
		7-27	3										
mADA2-pre 267	3-15	3-22	2	4	FYYDSSGYNRYFDY	15	1-39	2	QQSYSTPNT	9	+	-	-
mADA2-pre 274	4-31	3-10	2	4	EAYYGSGSKQQYSNFDY	17	4-1	1	QQYYSTPRT	9	+	+	+ (N)
mADA2-pre 277#	1-46	2-21	2	4	DKGGLDDCGGECYHGAPNDY	20	3-11	4	QQRSNWPLT	9			
mADA2-pre 278	3-21	3-10	3	4	DLWLVRGVIDW	11	3-15	1	QQYNNWPPWT	9	+	+	+ (N)
mADA2-pre 287#	4-34	3-10	3	5	GTRIYRIMVRGVGGWFDP	18	3-20	1	QQYGSSPT	8			
mADA2-pre 290	4-59	5-5	2	2	GGRFGYSYGSNWYFDL	16	3-20	3	QQYGSSPPFT	10	+	+	+ (C)
mADA2-pre 50							1-39	1	QQSYSTPQT	9			
mADA2-pre 51							1-16	4	QQYNSYPLT	9			
mADA2-pre 56							3-11	5	QQRSNWIT	8			
mADA2-pre 66							2-28	1	MQALQTTWT	8			
mADA2-pre 73							2-28	4	MQALQTSFSLT	11			
mADA2-pre 77							1-39	2	QQSYSTYT	8			
mADA2-pre 78							1-6	1	LQDYNYPRT	9			
mADA2-pre 89							3-20	1	QQYGSSPYVT	10			
	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	Poly	Hep2	Staining
mADA2-pre 250	3-23	/	/	4	EGWRPLFDY	9	2-14	3	SSYTSSSTWV	10	-	-	-
mADA2-pre 251	4-39	2-2	3	5	QNIVVPAAIAYWFDP	16	1-51	3	GTWDSLSAGV	11	-	-	-
mADA2-pre 260	3-23	1-26	3	4	RKVGATKPIDY	11	3-21	7	QVWDSSTAV	9	-	-	-
mADA2-pre 269#	3-7	1-26	2	4	DWVERDSGSYGY	12	2-14	2	SSYTSSSTLV	10			
mADA2-pre 276	4-30-4	6-6	1	4	ALYEQLVCFDY	12	1-51	3	GTWDSLSALL	11	-	-	-
mADA2-pre 288	1-18	1-26	1	4	DEGWELFAGDY	11	2-18	3	SSYTSSSTWV	10	-	-	-
mADA2-pre 293	3-7	6-6	3	4	GGARRCDY	8	2-8	2	SSYAGSNNFVV	11	+	+	+ (N)
mADA2-pre 296#	4-34	7-27	LG	5	GLGAVIAADKARFDP	15	1-47	3	AAWDDSLSGRV	11			
	VH	D	RF	JH	CDR3 (aa)	Length							
mADA2-pre 257	3-66	3-10	1	6	AKPDERFGELLETFYGM DV	20							
mADA2-pre 280	3-30	1-26	1	4	AKTWELLDY	9							
mADA2-pre 282	3-21	6-6	1	4	VITFSARQLEFDY	13							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 10: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 3 before gene therapy

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	Vk	Jk	CDR3 (aa)	Length	Poly	Hep2	Staining
mADA3-pre 49#	3-66	/	/	4	VLLTVYYFDY	11	3-15	5	QQYNNWPIT	9			
mADA3-pre 51	4-34	3-22	2	4	GQNYDSSGSFYFDY	16	3-20	1	QQYGSSPRT	9	-	-	-
mADA3-pre 55	4-34	6-19	1	4	EGLVRSYFDY	10	1-39	1	QQSYSTPRT	9	-	-	-
mADA3-pre 61	3-23	6-13	2	4	DISSSGNYFDY	13	1-39	1	QQSYSTPRT	9	+	+	-
mADA3-pre 62	4-b	2-2	2	5	DAPEYCSSTSCSNWFDP	19	3-11	4	QQRSNWPLT	9	-	-	-
mADA3-pre 66	3-48	5-12	2	6	DRRGYSGYDFRFGGMDV	17	1-33	4	QQYDNLPLT	9	+	+	+(C)
mADA3-pre 67	4-31	/	/	5	DRTRNNWFDP	10	1-33	4	QQYDNLPLT	9	-	+	+(C+N)
mADA3-pre 71	3-33	2-2	3	4	DTGVVPAAYFDY	12	1-27	3	QKYNSAPFT	9	-	+	+(C+N)
mADA3-pre 74	3-21	4-23	2	4	GIGNSFDY	8	1-8	1	QQYYSYPT	9	+	+	+(C)
mADA3-pre 75	3-11	3-22	2	4	EDPFDSSGYLDY	13	1-39	3	QQSYSTPFT	9	-	-	-
mADA3-pre 77	3-49	3-16	2	4	FDYLVYD	7	3-20	2	QQYGSSPYS	9	-	-	-
mADA3-pre 78	4-31	3-22	2	4	ESRTGYDSSPYFDY	15	3-20	1	QQYGSSPRT	9	-	+	+(C)
mADA3-pre 79	3-53	3-22	2	4	LYDSSGYPFYD	12	1-39	2	QQSYSTPPYT	10	-	+	+(N)
mADA3-pre 80#	3-33	6-13	3	4	PSRPRSEGIAAAGAYFDY	19	1-33	5	QQYDNLPLT	9			
mADA3-pre 81#	3-30	1-26	2	4	GGSLDY	6	1D-17	4	LQHNSYPLT	9			
mADA3-pre 84	1-69	1-26	3	5	REVVGWFDP	10	1-33	4	QQYDNLPLT	9	+	-	-
mADA3-pre 85	1-8	2-2	3	6	GPVPAAITDYGGMDV	18	3-20	2	QQYGSSPPYT	10	-	-	-
mADA3-pre 87	3-33	3-3	1	5	GGVQWFHP	8	2-30	4	MQGTHWPLT	9	+	+	+(C+N)
mADA3-pre 88	3-66	/	/	6	DRDYGGMDV	12	3-20	4	QQYGSSPRLT	10	+	+	+(C)
mADA3-pre 91	1-69	7-27	3	6	GYYYGMDV	8	3-15	1	QQYNNWPWT	9	+	+	+(C)
mADA3-pre 92	1-2	1-26	3	4	DHGWGIVGAMVY	12	3-15	1	QQYNNWPWT	10	+	+	+(N)
mADA3-pre 94	3-15	6-19	2	4	VGSSGWLSFDY	11	1-39	2	QQSYSTPYT	9	+	+	+(C)
mADA3-pre 95	3-30	1-26	1	4	GELLY	6	3-15	4	QQYNNWPPLT	10	+	+	+(C+N)
mADA3-pre 50							1-5	1	QQYNSYPWT	9			
mADA3-pre 53							1-5	2	QQYNSYPYT	9			
mADA3-pre 60							3-20	4	QQYGSSPPLT	10			
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	Poly	Hep2	Staining
mADA3-pre 52	5-51	3-10	3	6	QDRITMVRGVITYYYYGMDV	21	1-51	3	GTWSSLSAGV	11	+	-	+(C+N)
mADA3-pre 54	4-31	2-21	2	3	IYCGDCYRRDAFDI	16	1-51	2	GTWSSLSAVV	11	+	+	+(C)
mADA3-pre 55					see kappa		3-1	2	QAWDSSTV	9	-	+	+(C)
mADA3-pre 56	3-15	5-12	2	4	HGYSSTRDY	9	4-60	3	ETWDSNTQV	9	-	-	-
mADA3-pre 63	4-39	2-2	2	4	HCSSTSCYSGDDY	13	2-11	3	CSYAGSYTLRV	11	-	-	-
mADA3-pre 68	3-21	/	/	6	DWSDFYGMDV	10	1-47	3	AAWDDSLSGWV	11	-	-	-
mADA3-pre 69	3-30	4-17	2	3	RESDYPWEDAFDI	13	8-61	3	VLYMGSGIWW	10	-	-	-
mADA3-pre 72	3-74	2-15	2	4	VAGYCSGGSCYFFDY	15	3-21	2	QVWDSSTDHVV	11	-	-	-
mADA3-pre 86	4-61	3-22	2	3	VGNYSPPFDI	10	2-14	1	SSYTSSTRYV	11	+	+	+(C)
mADA3-pre 89	1-2	/	/	3	TFGRDGFDAFDI	12	1-44	3	AAWDDSLNGPV	11	-	-	-
mADA3-pre 90	1-2	3-22	2	3	PYDSSGYHHAFDI	14	2-11	1	CSYAGSYTYV	10	+	+	+(C)
mADA3-pre 93	3-15	/	/	4	RRVGWKVDY	9	3-25	2	QSADSSGTYVV	11	+	+	+(F)
mADA3-pre 96	3-21	2-21	2	6	CGGDCYSDYGGMDV	14	3-25	1	QSADSSGTYV	10	-	+	+(N)
	VH	D	RF	JH	CDR3 (aa)	Length							
mADA3-pre 57	3-66	6-6	2	2	ESGSSSYWYFDL	12							
mADA3-pre 59	3-49	3-22	2	3	EEYDSSGYPDAFDI	15							
mADA3-pre 65	3-30	7-27	3	4	DHSAGDGGY	9							
mADA3-pre 70	4-61	3-10	3	5	VRGARVDP	8							
mADA3-pre 73	3-33	6-19	2	4	DRDPYSSGWYLDY	13							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 11: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 1 after gene therapy

Ig	HEAVY						LIGHT				GT			REACTIVITY
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	NeoR	Poly	Staining	
neADA1-post 01#	3-48	3-3	2	3	ADYDFWSGYYLGAFDI	16	3-20	1	QQYGSSTRT	9	+			
neADA1-post 03	4-39	2-15	3	4	RGVGDIVVVAATYDY	15	1-39	3	QQSYSTPFT	9	+	+	+ (C)	
neADA1-post 05	3-20	2-2	2	4	GRDCSSTSCYYFDY	14	3-11	4	QQRSNWPPPT	9	+	-	-	
neADA1-post 13	4-b	3-3	3	4	LPTIFGVADDY	11	1D-17	4	LQHNSYPLT	9	+	-	-	
neADA1-post 14	4-34	6-19	2	4	GSGRGSWYFFDY	13	3-20	2	QQYSSMCS	9	-	-	-	
neADA1-post 16#	3-21	2-8	2	6	ATYCTGGVCYNGVEKGYYYYYMDV	24	1D-12	1	QQANSFPWT	9	+			
neADA1-post 17#	1-2	3-3	2	4	NRFWSGYQIDY	11	2-40	1	MQRIEFQT	8	-			
neADA1-post 18	1-2	6-13	3	2	DMKGASAAGLNWYFDL	16	1-5	5	QQYNSYSIT	9	+	-	-	
neADA1-post 19#	3-11	3-3	2	5	YDFWSGYTPNWFDP	15	1-5	1	QQYNSYPWT	9	-			
neADA1-post 21#	4-b	3-3	3	6	DSAVTIFGVDSYMDV	17	1-5	1	QQYNSYPT	8	-			
neADA1-post 23	4-59	3-10	2	6	HNYYGSGSYNLYYYYYGMDV	21	4-1	4	QQYYSTPLT	9	+	-	-	
neADA1-post 24	4-59	6-13	2	6	SNSSSSWYDERYGMDV	16	4-1	1	QQYYSTPWT	9	+	-	-	
neADA1-post 25	4-39	6-13	2	6	DGRQDSSSWYYYYYGMDV	17	3-11	5	QQRSNWPPVT	10	+	+	+ (C)	
neADA1-post 26	3-23	6-19	1	4	GQWLVPYFDY	10	3-11	4	QQRSNWPLT	9	+	-	-	
neADA1-post 29#	3-23	3-16	3	4	DSPMITFGGVVVPFDY	16	3-11	5	QQRSNWPPIT	10	+			
neADA1-post 35	4-59	3-10	2	4	SPPWRYYYGSGSYVFDY	17	3-15	4	QQYNNWPLT	10	+	+	+ (C)	
neADA1-post 38	3-48	6-19	1	4	DIGQWLVPYFDY	13	3-15	2	QQYNNWSYT	9	+	-	-	
neADA1-post 42#	3-30	5-12	2	4	DRVYSGYDLIDY	12	2-29	2	MQGIHLPT	8	+			
neADA1-post 48	4-b	3-16	3	5	DPEFGQVRFDP	11	1-9	2	QQLNSYPLCS	10	+	+	-	
neADA1-post 09							3-15	3	QQYNNWPT	8	-			
neADA1-post 45							1-39	2	QQSYSTLRS	9	-			
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	NeoR	Poly	Staining	
neADA1-post 02	3-53	/	/	6	GYGMDV	6	6-57	2	QSYDSSTHVV	10	+	-	-	
neADA1-post 04	3-21	3-16	1	4	DASRHLGELSSPMGIAGVGTFDY	25	2-14	2	SSYTSSSTPVV	11	-	-	-	
		6-19	3											
neADA1-post 06	4-39	1-26	3	4	ETDLKRWVGATFYFDY	16	1-51	2	GTWDSSLSAGV	11	-	-	-	
neADA1-post 08	1-18	1-7	1	3	VPTTSLELLDAFDI	14	2-23	3	CSYAGSSTWV	10	+	-	-	
neADA1-post 10	4-30-4	6-19	3	4	VAGRHFYD	8	1-51	2	GTWDSSLSAGPYVV	14	+	-	-	
neADA1-post 17	1-2	3-3	2	4	NRFWSGYQIDY	11	2-14	1	SSYTSSSTYV	10	-	+	+ (C)	
neADA1-post 22	1-46	6-6	2	4	GYDKEYSSSSCEGY	14	1-44	1	AAWDDSLNGYV	11	-	-	-	
neADA1-post 27#	3-30-3	6-6	2	3	IEYSSSSRAFDI	12	3-10	2	YSTDSSGNHRV	11	+			
neADA1-post 28	3-11	6-19	1	3	DRSATSPWLVRSESHDAFDI	20	2-14	3	SSYTSSSTWV	10	-	-	-	
neADA1-post 30#	1-2	3-9	2	3	NMTAYYDILTGYFSDQEFDAFDI	24	2-14	7	AAWDDSLNGAV	11	+			
neADA1-post 32	4-30-4	2-2	2	4	AGYCSSTSCYRGKNYFDY	18	2-14	1	SSYTSSSTYV	10	+	-	-	
neADA1-post 33	1-2	3-3	2	4	LYYDFLDY	9	1-51	1	GTWDSSLSAGPYV	13	-	-	-	
neADA1-post 36	3-13	3-16	1	4	GLHLGELSLVDY	12	2-14	2	SSYTSSSTLVV	11	+	-	-	
neADA1-post 40	3-23	4-17	3	4	NDPISTVTDY	10	3-21	2	QVWDDSSDHVV	11	-	-	-	
neADA1-post 47	5-51	6-13	3	4	QPLIAGVSDY	11	2-8	2	SSYAGTHVV	9	+	-	-	
neADA1-post 29							3-25	3	QSADSSGTYWV	11	+			
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR			
neADA1-post 44	3-7	4-17	3	6	EPLTTWGYYYYYGMDV	17					+			

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 12: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 2 after gene therapy

	HEAVY					Length	LIGHT			Length	NeoR	REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)		Vk	Jk	CDR3 (aa)			Poly	Staining	
neADA2-post 02#	4-4	/	/	4	RETYFGY	7	3-20	4	QQYGSSPLT	9	+			
neADA2-post 05#	1-2	3-22	2	4	ASSGYPYFDY	11	3-15	1	QQYNWPQT	9	+			
neADA2-post 22#	3-33	1-7	1	4	DELEDFIDY	10	2-28	4	MQALQIPLT	9	+			
neADA2-post 38#	3-9	6-13	2	4	GSYSSWYLPFDY	13	1-5	2	QQYNSYPYT	9	+			
neADA2-post 41#	3-30	5-5	2	1	WGGYSYGTAYFQH	13	3-20	1	QQYGSSLSWT	10	+			
neADA2-post 46#	3-23	3-22	2	4	DQGYDSSGYYPLDY	15	1-39	1	QQSYSTPRT	9	+			
neADA2-post 48#	4-59	/	/	4	VHSGRIFDY	9	1-33	3	QQYDNLPT	9	-			
neADA2-post 104#	1-2	3-22	2	4	YYDSSGTPDY	10	1-5	4	QQYNSYPLT	9	+			
neADA2-post 116	3-23	1-26	3	4	SEAVGAGVYFDY	13	1-39	1	QQSYSTPWT	9	-	-	-	
neADA2-post 119#	4-61	1-7	3	4	DGDITGTMGLDY	13	1D-17	1	LQHNSYPRT	9	+			
neADA2-post 127#	3-7	3-10	1	4	DQVFGGLWFGEDY	14	1-27	2	QKYNAPYT	9	+			
neADA2-post 133	3-30	7-27	3	4	GGAGDESPYFDY	13	1-8	4	QQYYSYPLT	9	+	-	-	
neADA2-post 135	3-43	6-19	3	4	DPTVAGTRLDY	11	3-15	1	QQYNNWPPWT	10	+	-	-	
neADA2-post 139#	1-69	6-13	3	4	AVAAAGRDPGYFDY	14	3-20	4	QQYGSSPLT	9	+			
neADA2-post 143	3-48	6-19	2	4	DGSPHSGWAPPYFDY	15	1-39	2	QQSYSTLMYT	10	-	-	-	
neADA2-post 201	3-30	2-2	3	6	DPLQVPAESDYGGMDV	18	2-30	4	MQGTHWPLT	9	+	-	-	
neADA2-post 202	1-18	5-5	2	4	THSSYSYGRGAGAFDY	17	3-15	2	QQYNNWPYT	9	-	+	-	
neADA2-post 203	3-48	4-17	2	4	DGDYGDYQHSSGNY	14	2-28	2	MQALQTPYT	9	+	-	-	
neADA2-post 206#	1-3	4-4	2	4	MADDYSNRYFDY	13	4-1	1	QQYSTPWT	9	-			
neADA2-post 207#	1-69	3-22	2	6	DPPGYDSSGYPDV	14	1-17	4	LQHNSYPLT	10	+			
neADA2-post 212	3-66	3-22	2	4	VGDYDSSGYSVLD	14	1-8	4	QQYYSYPLT	9	+	-	-	
neADA2-post 214	3-43	3-22	2	4	DSWYDSSGYFDY	13	2-30	2	MQGTHWPPYT	10	+	-	-	
neADA2-post 215	4-4	6-19	3	6	DLTAVAGTYGGMDV	14	3-11	2	QQRSNWPPYT	10	-	-	+	(N)
neADA2-post 217	4-59	4-23	3	3	DQTTVANAFDI	11	3-15	4	QQYNNWPL	8	+	-	-	
neADA2-post 218	1-46	2-8	2	6	DNRGYCTNGVCNYYYGMDV	19	1-39	1	QQSYSTPWT	9	+	-	-	
neADA2-post 220	3-43	6-13	3	6	DQVAAAGTLGYYYYGMDV	19	2D-29	1	MQSIQLPRT	9	+	-	-	
neADA2-post 226	3-15	2-2	3	6	RGNEVPAAPGWGMDV	17	2D-28	2	MQALQTPMYT	10	-	-	-	
neADA2-post 228	1-58	6-13	3	4	DGIAAAGNQLDY	12	2-28	4	MQALQTLT	8	+	-	+	(C)
neADA2-post 231	3-53	6-19	1	4	SSEQWLARGYFDY	14	1-5	2	QQYNSLYT	8	+	+	+	(C)
neADA2-post 235	3-30	1-26	2	6	DGRDAYSGSYGGMDV	16	2-28	4	MQALQTPQLT	10	+	-	-	
neADA2-post 238	4-39	6-13	2	4	RYSSSWIDY	9	1-5	1	QQYNSYSWT	9	+	+	+	(C)
neADA2-post 240	4-34	2-15	3	4	GRILVVVAATPDYFDY	17	1-17	4	LQHNSYPLT	9	-	-	-	
neADA2-post 241	4-59	7-27	3	4	ETGGPTDY	9	1-5	4	QQYNSYPLT	9	+	-	-	
neADA2-post 244#	4-34	3-9	2	4	GRVHYDILTGLYFFEY	17	3-11	3	QQRSNWPPGGLFT	13	+			
neADA2-post 245	4-59	3-9	2	4	GSWVDYDILTYLLD	15	3-11	3	QQRSNWVIT	9	+	+	+	(C)
neADA2-post 248	4-4	5-12	2	4	GDYSGDPNGYFDY	14	3-11	4	QQRSNWPLT	9	-	-	-	
neADA2-post 12							1-6	1	LQDYNPRT	9	+			
neADA2-post 16							1-39	1	QQSYSTPWT	9	+			
neADA2-post 31							1-33	3	QQYDNLPT	8	+			
neADA2-post 40							1-39	4	QQSYSTPLT	9	+			
neADA2-post 224							3-20	3	QQYGSSPFT	9	+			
neADA2-post 232							1-5	2	QQYNSYSPYT	10	+			
neADA2-post 234							1-27	1	QKYNAPLT	9	+			
neADA2-post 242							1-39	2	QQSYSTPLT	9	+			
neADA2-post 243							1-17	2	LQHNSYQYT	9	+			
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	NeoR	Poly	Staining	
neADA2-post 09#	1-46	5-5	3	4	VDTAMRQGDY	10	3-21	1	QVWSSSDHYV	11	+			
neADA2-post 105	3-9	/	/	4	DKGMG	5	4-69	3	QVWGTGIHVV	10	+	-	-	
neADA2-post 205#	3-30	3-9	2	4	DRGYDILTYGSDY	13	3-21	3	QVWSSSDHPV	11	+			
neADA2-post 209	3-74	1-26	2	4	DTLHSGSYWPDY	12	3-21	2	QVWSSSDHVV	11	+	-	-	
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR			
neADA2-post 03	3-23	2-2	3	5	DLREDVVVPLGGWFDP	17					+			
neADA2-post 210	3-48	/	/	3	DSAIRRYSDAFDI	13					+			
neADA2-post 211	3-15	4-17	3	4	EATVTTFIEIRNFDY	15					+			
neADA2-post 225	3-23	2-2	2	4	AYGCSSTSCYEGYFDY	19					+			
neADA2-post 233	4-59	/	/	4	DGDGFDY	7					+			
neADA2-post 236	3-66	/	/	4	DLSFSN	6					+			
neADA2-post 239	4-34	6-13	3	4	GEAGIAAGALYFFDY	16					+			
neADA2-post 246	3-13	6-19	3	6	ALRGAVAGILSGILSGDYGGMDV	24					+			
neADA2-post 08	1-46	/	/	4	ESSYFEY	7					+			
neADA2-post 123	4-39	5-5	2	4	LQGYSYGIDY	10					+			
neADA2-post 204	1-2	3-10	3	4	EVKITMVRGYFFDY	14					+			
neADA2-post 213	3-7	4-17	3	6	DHTVTTYGGMDV	13					+			
neADA2-post 221	4-39	2-8	2	1	LGCTNGVCPVFOH	14					+			
neADA2-post 223	4-59	/	/	4	AASYFDY	7					+			
neADA2-post 229	3-66	7-27	2	4	DLGDTGYFDY	10					-			
neADA2-post 230	4-30-4	3-22	2	4	APANFNYYDSSGYSY	15					+			
neADA2-post 237	3-43	4-23	3	6	IMSARDTVVTTYRGDLYYYYGGMDV	25					+			

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 13: Repertoire and reactivity of antibodies from new emigrant B cells of ADA-SCID patient 3 after gene therapy

Ig	HEAVY						LIGHT				GT	REACTIVITY		
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length		NeoR	Poly	Staining
neADA3-post 08	1-2	3-22	2	4	DGGTYYYDSSGYRFDY	16	3-20	4	QQYGSSPLT	9	+	-	-	
neADA3-post 10	3-23	2-15	2	4	TSAGYCSGGSCLEFILEFWPYFDY	23	3-15	1	QQYNNWPPWT	10	+	+	+ (C)	
neADA3-post 12#	3-23	2-21	2	3	GFASYCGGDCHVGDAFDI	18	1-8	5	QQYYSYPIT	9	+	-	-	
neADA3-post 13	3-21	1-26	2	3	ADDSPYSGSYSPGAFDI	20	1-5	1	QQYNSYST	8	+	-	-	
neADA3-post 14	3-21	1-20	2	4	DFGSGGNWNPDLDY	14	2-28	4	MQALQTPQLT	10	-	-	-	
neADA3-post 15	4-39	2-15	2	4	TKDLGYCSGGSCYSYFY	18	3-15	2	QQYNNWPPYS	10	+	-	-	
neADA3-post 16	3-9	1-26	2	1	DSGSYFEAEYFQH	13	3-20	5	QQYGSSTP	8	+	-	-	
neADA3-post 17	3-7	1-7	2	4	ETNWIGY	7	1-27	3	QKYNSAPPNT	10	+	-	-	
neADA3-post 18	1-69	3-22	2	4	HSSGYFFDY	9	1-39	1	QQSYSTPRT	9	+	+	+ (C)	
neADA3-post 20	1-69	3-22	2	1	TYYDSSGYLQDPVGYFQH	19	4-1	4	QQYYSTPLT	9	+	-	-	
neADA3-post 22	3-43	6-19	3	3	GNQARIGPISIAVAPKDAFDI	22	2-30	2	MQGTHWPPYS	10	+	-	-	
neADA3-post 23	4-31	3-10	3	5	DPGVRGVSYWFDP	13	4-1	3	QQYYSPT	9	+	-	-	
neADA3-post 25	3-15	3-22	2	4	DLPLDYDSSGYDY	16	3-11	1	QQRSNWPWT	9	+	-	+ (C)	
neADA3-post 27	3-30	6-13	2	4	EKYSSWYVYFDY	14	3-11	4	QQRSNWPLT	9	+	+	-	
neADA3-post 28	3-30	6-19	2	6	DQQGYSSGWSTDLYYYYYGMVDV	24	1-8	2	QQYYSYPYS	9	+	+	+ (C)	
neADA3-post 36	4-31	2-2	3	6	DWVVVPAAKFTGTNNYYGMVDV	23	1-39	2	QQSYSTPYS	9	-	-	-	
neADA3-post 37	1-8	3-3	1	4	APPRFLEFN	9	1-39	4	QQSYSTPLT	9	-	-	-	
neADA3-post 39	1-2	1-26	2	4	DTTRGSYDRGGYDY	15	4-1	3	QQYYSFTPT	9	+	-	+ (C)	
neADA3-post 40	1-2	3-10	3	6	ERMVPVKEYYYYGMVDV	17	1-5	4	QQYNSYSLT	9	+	-	+ (C)	
neADA3-post 41#	1-69	2-2	2	3	RYCSSTSCYSGAFDI	15	3-15	1	QQYNNWPPWT	10	-	-	-	
neADA3-post 42	4-34	7-27	1	2	GKEEKLGTPPFYWYFDL	17	1-5	4	QQYNSYPLT	9	+	-	-	
neADA3-post 43	3-23	6-6	2	4	DRGWYSSSNYFDY	14	3-11	5	QQRSNWPIT	9	+	+	-	
neADA3-post 44	3-53	/	/	4	VGRLDYFDY	9	3-20	2	QQYSSPMYS	10	+	-	-	
neADA3-post 46#	5-51	2-2	3	3	QDIVVPAAMDAFDI	15	3-20	1	QQYGSSTPRT	9	-	-	-	
neADA3-post 07							1-8	1	QQYYSYPRT	9	+	-	-	
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	NeoR	Poly	Staining	
neADA3-post 02	3-33	/	/	6	ESSGMDV	7	1-40	1	QSYDSSLSAPYV	12	+	-	-	
neADA3-post 04	5-51	5-5	3	4	QVGD TAMV SFNYFDY	15	2-11	2	CSYAGSYTVV	10	+	-	-	
neADA3-post 05	3-11	2-2	2	5	DNCMYGSSSTSCYDP	14	1-44	1	AAWDDSLNGYV	11	-	-	-	
neADA3-post 06#	3-15	3-3	3	4	DPESITIFGVVY	13	2-14	1	SSYTSSTYV	10	-	-	-	
neADA3-post 07	4-34	3-22	2	4	LSYYDSSGEGDY	12	1-47	3	AAWDDSLSGSWV	12	+	-	-	
neADA3-post 08	1-2	3-22	2	4	DGGTYYYDSSGYRFDY	16	3-1	2	QAWDSSTVV	9	+	-	+ (C)	
neADA3-post 11	3-48	6-19	2	4	ALSSSGYVFDY	11	3-1	3	QAWDSSTAWV	10	-	-	-	
neADA3-post 19	1-8	3-10	1	4	GMIVGEGVFFGDY	13	3-25	3	QSADSSGTWV	10	+	-	-	
neADA3-post 21	4-31	3-22	2	2	SYDSSGYWYFDL	12	2-14	3	SSYTSSTLGV	11	-	-	-	
neADA3-post 24	4-4	2-15	2	6	DPGYCSGGSCYLDYYDMDV	20	2-23	3	CSYAGSSTFEV	11	+	-	-	
neADA3-post 29	4-31	/	/	5	RGSANNWFDP	10	3-21	2	QVWDSSTDHVV	11	+	-	-	
neADA3-post 37#	1-8	3-3	1	4	APPRFLEFN	9	3-25	2	QSADSSGTQV	11	+	-	-	
neADA3-post 38	3-9	3-22	2	4	MKGSSGYVFDY	12	3-21	3	QVWDSSTDRNVV	12	+	-	-	
neADA3-post 45	1-2	3-3	2	5	DRSGASIRFNWFDP	14	1-44	2	AAWDDSHVV	9	+	-	+ (C)	
neADA3-post 47	4-39	4-17	2	5	RDGDYPFNWFDP	12	1-40	2	QSYDSSLSVV	10	-	-	-	
neADA3-post 30							3-1	2	QAWDSSTVV	9	+	-	-	
neADA3-post 31							3-1	3	QAWDSSTAWV	10	+	-	-	
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR			
neADA3-post 09	3-11	2-15	2	6	DGYRGCSGGSCYSSYYGMDV	20					+			

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 14: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 1 after gene therapy

Ig	HEAVY						LIGHT				GT				REACTIVITY			
	VH	D	RF	JH	CDR3 (aa)	Length	V _κ	J _κ	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA1-post 51	7-4-1	6-19	2	5	GGLGYSSVEWWFDP	14	3-15	1	QQYNNWPRT	9	-	-	-	-				
mADA1-post 52	4-b	6-13	2	4	EEISSSWYSGGVYD	14	1-27	3	QKYNSAPFT	9	+	+	+	-				
mADA1-post 58#	4-59	4-17	2	4	HDDYGDYYFDY	11	1-39	2	QQSYSTPYT	9	+							
mADA1-post 62#	4-34	4-17	3	3	GLLLRVTTRVAFDI	15	1-16	3	QQYNSYPFT	9	+							
mADA1-post 63#	1-18	2-15	3	3	GRSDIVVVAELDAFDI	18	1-27	3	QKYNSAPFT	9	+							
mADA1-post 67	4-34	6-13	3	5	GIAAAGTFRDPNWFDP	16	4-1	1	QQYYSTPWT	9	+	-	-	-				
mADA1-post 70#	1-2	6-6	2	4	LLYSSSSWDFDY	12	1-16	5	QQYNSYPIT	9	+							
mADA1-post 72	3-15	3-10	2	6	DYSGSGYYYYYGMV	16	1-33	3	QQHDNLPLT	9	-	-	-	-				
mADA1-post 75	3-9	2-15	2	4	DITSSGGSGGSCYSS	15	3-15	2	QQYNNWPCS	9	+	+	+	+(C)				
mADA1-post 81#	4-59	6-13	3	4	ETHIAAAGRAYYFDY	15	3-20	5	QQYGSSIT	8	+							
mADA1-post 84#	3-15	2-15	2	4	RPYCSGGSCYSFFHY	15	3-15	1	QQYNNWPPT	9	-							
mADA1-post 86	3-21	3-3	3	4	RVFGVANLYYFDY	13	3-11	4	QQRSNWPLT	9	+	+	-	-				
mADA1-post 87#	3-23	5-12	3	4	DRVNDY	7	3-11	1	QQRSNWPPWT	10	-							
mADA1-post 88#	4-b	3-22	2	5	EGYFLPLDYDSSP	13	3-11	1	QQRSNWPPWT	10	+							
mADA1-post 90#	1-3	1-26	2	3	YSGSYFLDAFDI	12	3-20	4	QQYGSSLT	8	+							
mADA1-post 92#	1-2	2-15	3	3	ASIVVVAATRIYDAFDI	18	2-28	2	MQALQTPRT	9	+							
mADA1-post 54							3-20	4	QQYGSSPLT	9	+							
	VH	D	RF	JH	CDR3 (aa)	Length	V _λ	J _λ	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA1-post 55	1-8	/	/	2	GGVNIFDL	8	1-36	1	AAWDDSLNGYV	11	+	-	-	-				
mADA1-post 59	4-4	/	/	4	VNIWIDY	7	2-11	1	CSYAGSYTFPYV	12	+	+	+	+(C)				
mADA1-post 65	3-48	2-15	3	3	DLPRLPLRVAATFAFDI	18	2-14	2	SSYTSSSTLVV	11	+	-	-	-				
mADA1-post 66#	1-18	4-17	2	4	RAYGDYLPGFYD	12	7-43	2	LLYYGGAQLV	10	+							
mADA1-post 68	4-59	4-17	2	1	SYGDYVVEYFQH	12	2-11	2	CSYAGSYTLV	10	+	-	-	-				
mADA1-post 71	4-39	6-19	3	4	LVLYSMTGIDY	11	2-23	2	CSYAGSSTLV	10	-	-	-	-				
mADA1-post 74	1-18	3-10	1	4	NGLLWFRELLSLYFDY	17	1-44	3	AAWDDSLNGWV	11	+	+	+	+(C)				
mADA1-post 77#	3-33	2-21	2	4	EGNAYCGGDPCPFYD	14	3-21	2	QVWDSSSDHHVV	12	+							
mADA1-post 80	1-69	4-23	2	4	SQGRTYDYGNSPFYD	16	2-11	2	CSYAGSYTSVV	11	-	+	-	-				
mADA1-post 83	1-8	4-17	2	6	ASYGDYYYYYMDV	14	1-44	2	AAWDDSLNGVV	11	+	-	-	-				
mADA1-post 91	3-11	7-27	3	2	ELTEPYWYFDL	11	2-8	1	SSYAGSNKLGV	11	+	-	-	-				
mADA1-post 96#	1-2	3-10	2	5	VAYYGSGLNWFDP	14	3-21	3	QVWDSSSDHHVV	11	-							
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR							
mADA1-post 57	3-23	6-6	2	4	DRWEGRSSSFSPTYD	14					-							
mADA1-post 69	3-9	6-13	3	4	ASSLIAAAGFDY	12					+							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 15: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 2 after gene therapy

Ig	HEAVY						LIGHT				GT				REACTIVITY			
	VH	D	RF	JH	CDR3 (aa)	Length	Vκ	Jκ	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA2-post 85#	4-39	6-19	3	4	HRIAVAGDFDY	11	1-33	4	QQSGT	5	+							
mADA2-post 186	3-30	3-10	1	4	DPRRFGELFPYYFDY	15	1-5	2	QQYNSYSMYT	10	+	-	-	-				
mADA2-post 255	3-30	3-22	2	3	NYDSSGWPFDAFDI	15	4-1	2	QQYYSTPHT	9	-	-	-	-				
mADA2-post 258	3-64	2-15	2	2	ANCSGGSCYNNWYFDL	16	1-8	2	QQYYSYPYT	9	-	-	-	-				
mADA2-post 265	3-21	6-13	1	4	ENEQQLVRELDY	12	1-5	1	QQYNSYSRT	9	+	-	-	-				
mADA2-post 267	3-43	1-26	2	4	DSPSSGSYRYFDY	13	1-33	2	QQYDNLPLYT	9	-	-	-	-				
mADA2-post 275	3-53	4-4	3	6	DVFRITTTVTYYGMDV	16	1-9	4	QQLNSYPLT	10	-	-	-	-				
mADA2-post 280	3-11	3-10	3	6	GLDTMVRGVIIDNHNYGMDV	22	2-28	3	MQALQTPIFT	10	-	-	-	-				
mADA2-post 283	3-21	6-13	2	4	DQVPRYSSSRFFYYFDY	17	3-15	1	QQYNNWPRAT	10	+	+	+	+				
mADA2-post 284#	3-23	2-2	3	4	DLILDIVVPAAILLDY	17	3D-15	5	QQYNNWPPVT	10	+							
mADA2-post 285#	1-58	/	/	6	EPKTVFNGAEHGMDV	15	1-39	4	QQSYSTP	7	+							
mADA2-post 287	3-33	2-2	2	6	DMGYCSSTSCLGVLKLYYYGMDV	24	1-39	3	QQSYSTPFT	9	+	+	+	+				
mADA2-post 290	3-48	4-23	2	3	PGGDYGNDAFDI	12	3-11	3	QQRSNWPPGGL	11	+	-	-	-				
mADA2-post 291	3-30-3	3-22	2	3	AYYYDSSGYVRAFDI	16	1-5	3	QQYNSYSGFT	10	+	-	-	-				
mADA2-post 293#	1-69	1-7	1	4	VRLEGMGKRYFFDY	14	3-15	1	QQYNNWPPWT	10	+							
mADA2-post 295	1-69	3-3	2	4	ETLQEERSGYLDY	13	3-11	4	QQRSNWPLT	9	+	-	-	-				
mADA2-post 64							3-20	3	QQYGSSAFT	9	-							
mADA2-post 73							1-5	2	QQYNSYSRA	9	+							
mADA2-post 96							1-5	2	QQYNSYLYT	9	+							
mADA2-post 52							1-33	4	QQYDNLPLT	9	+							
mADA2-post 66							3-15	1	QQYNNWPPWT	11	+							
mADA2-post 273							1-33	2	QQYDNLTYT	8	-							
mADA2-post 279							1-39	1	QQSYSTPRT	9	+							
mADA2-post 281							1-33	4	QQYDNLTL	8	-							
	VH	D	RF	JH	CDR3 (aa)	Length	Vλ	Jλ	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA2-post 53#	4-4	3-10	2	4	SRTYYYGSGSYNGPYFFDY	20	2-14	2	SSYTSSTLDV	12	-							
mADA2-post 56	3-48	6-13	3	4	IPLAADFDY	9	2-23	1	CSYAGSSTHYV	11	-	-	-	-				
mADA2-post 68	1-69	5-24	2	5	ESEGDYNYGNWFDP	14	1-40	3	QSYDSSLGWW	11	+	-	-	-				
mADA2-post 153#	3-7	/	/	4	EGGPPSVLDY	11	1-47	7	AAWDDSLGAV	11	+							
mADA2-post 156#	4-59	6-19	2	2	LGVSGWYVESYFDL	14	1-40	3	QSYDSSLGWW	11	-							
mADA2-post 157	4-30-2	/	/	2	GINWYFDL	8	3-21	3	QVWSSSDHPV	11	-	+	-	-				
mADA2-post 253	3-33	3-16	1	6	DVAQGGELSPYYYYGMDV	19	2-18	3	SSYTSSTLV	10	+	-	-	-				
mADA2-post 260	3-23	5-5	2	4	DLGYSYGYQYYFDY	14	2-14	3	SSYTSSTRV	10	+	-	-	-				
mADA2-post 263	3-23	6-19	2	4	ALPMYSSGGIYFDY	15	2-8	2	SSYAGSNNLV	10	+	-	-	-				
mADA2-post 274	3-30-3	3-10	1	4	GRSVKFGELLFVDY	14	2-18	3	SSYTSSTWV	10	+	-	-	-				
mADA2-post 286	3-21	3-10	2	4	SGNRGSGLSYLDY	13	3-21	3	QVWSSSDHWV	11	-	-	-	-				
mADA2-post 294#	1-69	1-1	1	4	VRLEGMGKRYFFDY	14	7-43	3	LLYYGGPWV	9	+							
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR							
mADA2-post 87	3-21	6-19	2	5	DGSYSSGWYGGNWFDP	16					+							
mADA2-post 169	1-46	3-22	2	4	VQSYDSSGYPNGYFDY	16					+							
mADA2-post 180	3-11	5-24	3	4	DPVLMATIGDYFDY	15					+							
mADA2-post 190	3-7	3-10	1	4	ADESPPWFGEFRVRLYFDY	22					-							
mADA2-post 256	3-21	2-15	2	6	FQYCSGGSCLGMDV	14					+							
mADA2-post 277	1-69	3-22	2	4	VGVGYDSSGYSPFDY	17					+							
mADA2-post 292	3-53	2-2	2	4	GSLPFSAFDY	10					+							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;
 C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 16: Repertoire and reactivity of antibodies from mature naive B cells of ADA-SCID patient 3 after gene therapy

Ig	HEAVY						LIGHT				GT				REACTIVITY			
	VH	D	RF	JH	CDR3 (aa)	Length	Vk	Jk	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA3-post 50	4-34	3-22	2	2	DYYDSSGLLRAYSWYFDL	18	1-33	4	QQYDNLPLT	9	-	-	-	-				
mADA3-post 53	3-30	3-22	2	4	DELRYDSSGLNYFDY	16	1-39	3	QQSYSTLFT	9	+	-	-	-				
mADA3-post 61	6-1	6-19	1	4	EPKPKSQWLHVGAIDY	16	1-39	1	QQSYSTPWT	9	-	+	+	+				
mADA3-post 63	3-30	1-7	2	3	EFRNYEGAFDI	11	4-1	4	QQYYSSSSST	10	-	-	-	-				
mADA3-post 64	6-1	6-6	2	5	SSHSPNWFDP	10	1-39	2	QQSYSTPPT	9	-	-	-	-				
mADA3-post 65	3-11	1-26	2	4	DRGGSYLRRGGFDY	13	1-33	3	QQYDNLFLT	9	-	-	-	-				
mADA3-post 71	4-39	3-22	2	4	PPGDYDSSGAHY	12	3-11	4	QQRSNWPPLT	10	-	-	-	-				
mADA3-post 75	1-2	7-27	3	4	LITGAQLDY	9	1-6	2	LQDYNYPPT	9	+	-	-	-				
mADA3-post 84	3-33	3-22	2	4	GPYYYDSSGYYYGYFDY	18	3-11	2	QQRSNWPPYT	10	+	-	-	-				
mADA3-post 85	4-61	3-10	2	4	GPAPYYYGSGSYRFDY	18	4-1	4	QQYYSTPLT	9	+	+	+	+				
mADA3-post 86	4-b	3-22	2	3	EGVAHYDSSGYYYDAFDI	18	3-20	1	QQYSSSRT	8	+	-	-	-				
mADA3-post 87	4-34	3-3	2	3	GIYDFWSGVRGAFDI	15	1-5	1	QQYNSYSRT	9	+	+	+	+				
mADA3-post 88	3-48	6-19	2	4	ALSSSGVYFDY	11	1D-8	1	QQYYSFPWT	9	+	-	-	-				
mADA3-post 89	3-21	6-19	3	4	DRPSLAVAGRCDY	14	3-11	4	QQRSNWPPLT	9	+	-	-	-				
mADA3-post 90	4-34	2-21	3	6	RMVVTATPYYYYGMDV	16	3-20	1	QLGSGT	6	+	-	-	-				
mADA3-post 91	5-51	3-3	1	2	LSFLEWLDQRYFDL	14	3-11	2	QQRSNWLMYT	10	+	-	-	-				
mADA3-post 96	3-23	3-3	2	4	DKDFWGYLRPLFDY	14	4-1	4	QQYSTPPLT	10	+	+	+	+				
mADA3-post 52							3-11	1	QQRSNWPWT	9	+							
mADA3-post 62							1-5	4	QQYNSYSLT	9	+							
mADA3-post 69							1-9	4	QQLNSYPLT	9	+							
mADA3-post 77							3-20	4	QQYGSSTL	8	+							
mADA3-post 80							3-20	2	QQYGSSPMYT	10	+							
mADA3-post 82							2-28	1	MQALQTPWT	9	+							
	VH	D	RF	JH	CDR3 (aa)	Length	V _L	J _L	CDR3 (aa)	Length	NeoR	Poly	Hep2	Staining				
mADA3-post 49#	4-34	5-5	1	5	TEIQLWYNWLDP	12	4-60	2	ETWDSNTRV	9	+							
mADA3-post 51	1-2	6-13	3	4	IHLKISAAGSKSFYFDY	17	3-21	2	QVWDSSSDHHVV	12	-	-	+	+(C+N)				
mADA3-post 70	1-69	3-22	2	4	DGYDSSGYYYFDY	13	2-23	2	CSYAGSVV	8	+	+	+	+(C)				
mADA3-post 73	1-8	2-2	2	6	TFPAFLGYCSSTSCYGHGYYYGMDV	26	1-44	2	AAWDDSLNGVV	11	+	-	-	-				
mADA3-post 74	4-34	7-27	1	3	PGLGRRSAFDI	11	2-14	1	SSYTSSSTRYV	11	+	-	-	-				
mADA3-post 76	3-11	3-10	1	4	YPTLLWFGEDKPSHFYD	17	2-11	2	CSYAGSYTVV	10	+	-	-	-				
mADA3-post 83	1-69	3-3	3	6	APVPITIFGVVTSTGYYYYGMDV	22	2-14	2	SSYTSSSPVV	10	+	+	+	+(C)				
mADA3-post 94	5-51	2-2	2	4	IRTRDCSSTSCYGGYFDY	18	2-14	1	SSYTSSSTLYV	11	+	-	-	-				
mADA3-post 77							3-1	3	QAWDSSTAWV	10	+							
mADA3-post 93							2-14	2	SSYTSSSTLV	10	+							
	VH	D	RF	JH	CDR3 (aa)	Length					NeoR							
mADA3-post 55	1-8	2-15	3	4	GPSHPNVVVAATEISDY	18					+							
mADA3-post 67	4-34	3-22	3	4	GREIVDMTLKPTDY	15					+							
mADA3-post 68	3-21	1-7	2	4	EENNWNYYGDY	10					-							
mADA3-post 72	4-34	1-26	3	4	AVGATHD	7					+							
mADA3-post 79	3-23	/	/	4	ANRRYFDY	8					+							
mADA3-post 95	1-46	4-4	3	6	VVETTFSYYYYGMDV	15					+							

RF, reading frame; #, antibody failed to be expressed; -, non-reactive; +, reactive;

C, diffuse cytoplasmic staining; S, mitotic spindle staining; N, nuclear staining; F, cytoplasmic fibers

Supplemental Table 17: Serum autoantibodies in ADA-SCID patients 6yrs postGT

GT	ADA1		ADA2		ADA3	
	preGT	postGT	preGT	postGT	preGT	postGT
Direct or indirect Coombs tests	-	-	N.D.	-	-	-
anti-neutrophil cytoplasmic antibodies (ANCA)	N.D.	-	N.D.	-	-	-
anti-liver kidney microsomal antibodies (LKM)	N.D.	-	N.D.	-	-	-
anti-smooth muscle antibodies	N.D.	-	N.D.	-	-	-

N.D., not done; -, non-reactive;